

Wednesday, October 15, 2025

Pre-conference workshop/course

09:30 - 09:35

AMPHITHEATRE BORDEAUX

Introduction

Introduction

Tristan Barber (United Kingdom)
Agnès Libois (Belgium)

09:30 - 09:35

Pre-conference workshop/course

09:30 - 09:40

ROOM MAILLOT

Opening and update

Opening and update

Annette Haberl (Germany)

09:30 - 09:40

Pre-conference workshop/course

09:35 - 10:20

AMPHITHEATRE BORDEAUX

Non AIDS Malignancies

Non AIDS Malignancies

Maria Mazzitelli (Italy)

09:35 - 09:55

Case Presentation

Risa Fukuoka (Japan)

09:55 - 10:10

Q&A/Discussion

10:10 - 10:20

Pre-conference workshop/course

09:40 - 10:20

ROOM MAILLOT

A Continental View: Epidemiology & Empowerment

Women with HIV: European Epidemiology

Charlotte Doegan (Sweden)

09:40 - 10:00

Current situation of women with HIV in Ukraine

Sergii Antoniak (Ukraine)

10:00 - 10:10

Discussion

Annette Haberl (Germany)
Dagny Krankowska (Poland)
Tetiana Melnyk (France)

10:10 - 10:20

Pre-conference workshop/course

10:20 - 10:40

AMPHITHEATRE BORDEAUX

Break

Pre-conference workshop/course

10:20 - 10:50

ROOM MAILLOT

Journeys of Strength: Migrant Women's Realities

SERAY Project

Giota Lourida (Greece)

10:20 - 10:30

Personal journey

10:30 - 10:40

Discussion

10:40 - 10:50

Nina Weis (Denmark)
Melvina Woode-Owusu (United Kingdom)
Cristiana Oprea (Romania)

Pre-conference workshop/course

10:40 - 11:25

AMPHITHEATRE BORDEAUX

HIV and Virology

HIV and Virology

10:40 - 11:00

Toshibumi Taniguchi (Japan)

Case Presentation

11:00 - 11:15

Matthew Valentino (Malta)

Q&A/Discussion

11:15 - 11:25

Pre-conference workshop/course

10:50 - 11:10

ROOM MAILLOT

Moving forward: Feeding Choices for Parents living with HIV

European guidelines on HIV and breastfeeding

10:50 - 11:00

Amy Keane (Ireland)

Discussion

11:00 - 11:10

Annette Haberl (Germany)

Mojgan Hessamfar (France)

Yvonne Gilleece (United Kingdom)

Pre-conference workshop/course

11:10 - 11:50

ROOM MAILLOT

Her Future, Her Terms: Ageing with HIV

Improving care for women with HIV as they age

11:10 - 11:30

Susan Cole-Haley (United Kingdom)

Anna Hachfeld (Switzerland)

Nneka Nwokolo (United Kingdom)

Models of care for women living with HIV in Europe: a scoping review

11:30 - 11:40

Duaa Rao (Germany)

Discussion

11:40 - 11:50

Ellen Moseholm (Denmark)

Anna Hachfeld (Switzerland)

Nneka Nwokolo (United Kingdom)

Susan Cole-Haley (United Kingdom)

Duaa Rao (Germany)

Pre-conference workshop/course

11:25 - 12:10

AMPHITHEATRE BORDEAUX

HIV Stigma in Healthcare Settings

HIV Stigma in Healthcare Settings

11:25 - 11:45

Agata Skrzat-Klapaczyńska (Poland)

Case Presentation

11:45 - 12:00

Yasmin Walters (United Kingdom)

Q&A/Discussion

12:00 - 12:10

Pre-conference workshop/course

11:50 - 12:10

ROOM MAILLOT

Break*Pre-conference workshop/course*

12:10 - 12:45

AMPHITHEATRE BORDEAUX

Break*Pre-conference workshop/course*

12:10 - 15:00

AMPHITHEATRE BORDEAUX

Afternoon Chairs

Jose I Bernardino (Spain)

Oana Sandulescu (Romania)

Pre-conference workshop/course

12:10 - 12:50

ROOM MAILLOT

Protection, Possibility, Power: Rewriting the Narrative with PrEP**Prevention of HIV, PrEP options for women**

12:10 - 12:30

Yvonne Gilleece (United Kingdom)

Educational needs assessment: PrEP in transcommunities

12:30 - 12:40

Paulie "Amanita" Calderón-Cifuentes (Germany)

Discussion

12:40 - 12:50

Nina Weis (Denmark)

Ben Collins (United Kingdom)

Maria Jesus Perez Elías (Spain)

Pre-conference workshop/course

12:45 - 13:30

AMPHITHEATRE BORDEAUX

HIV and Weight/GLP-1 Agonists**HIV and Weight/GLP-1 Agonists**

12:45 - 13:05

Marie-Angélique De Scheerder (Belgium)

Case Presentation

13:05 - 13:20

Carmen Busca (Spain)

Q&A/Discussion

13:20 - 13:30

Pre-conference workshop/course

12:50 - 13:20

ROOM MAILLOT

Silent Threat: HPV in Women living with HIV**HPV screening in women with HIV**

12:50 - 13:10

Christina Carlander (Sweden)

Discussion

13:10 - 13:20

Yvonne Gilleece (United Kingdom)

Nina Weis (Denmark)

Karoline Aebi-Popp (Switzerland)

Pre-conference workshop/course

13:20 - 13:30

ROOM MAILLOT

Closing remarks & next steps**Closing remarks & next steps**

13:20 - 13:30

Nina Weis (Denmark)

Pre-conference workshop/course

13:30 - 13:40

AMPHITHEATRE BORDEAUX

Break*Pre-conference workshop/course*

13:40 - 14:25

AMPHITHEATRE BORDEAUX

The Future of HIV Treatment**The Future of HIV Treatment**

13:40 - 14:00

Jose Arribas (Spain)

Case Presentation

14:00 - 14:15

Alexandra Riczu (Hungary)

Q&A/Discussion

14:15 - 14:25

Pre-conference workshop/course

14:25 - 14:50

AMPHITHEATRE BORDEAUX

Partner Presentations**EACS- European Diploma in HIV Medicine**

14:25 - 14:33

NEAT-ID

14:33 - 14:41

Esteban Martínez (Spain)

WEEPI

14:41 - 14:49

Jens D. Lundgren (Denmark)

Pre-conference workshop/course

14:50 - 14:55

AMPHITHEATRE BORDEAUX

Summary

Oana Sandulescu (Romania)

Pre-conference workshop/course

14:55 - 15:00

AMPHITHEATRE BORDEAUX

Future of YING, and Close

Jose I Bernardino (Spain)

Pre-conference workshop/course

10:00 - 12:00

ROOM 242AB

EATG STEPS Cure Workshop:**STEPS 11: The Giulio Maria Corbelli Workshop - A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection.****Welcome Note & Introduction to the Programme**

10:00 - 10:05

Daniela Rojas Castro (France)

Brian West (United Kingdom)

The Path to a functional HIV Cure: Fundamental Concepts & Current Updates, and an introduction to the EU2Control Platform

10:05 - 10:25

Mark Janse (The Netherlands)

Evy Blomme (Belgium)

Clinical Trials in the RHIVIERA Initiative

10:25 - 10:40

Cécile Goujard (France)

What French people with HIV can teach us about HIV Cure Research

10:40 - 10:55

Christele Protière (France)

RT TACK Mechanism

10:55 - 11:10

Luisa Stamm (United States)	
Update on therapeutic vaccines and immunotherapies for an ART-free control	11:10 - 11:25
Beatriz Mothe (Spain)	
Community Perspective	11:25 - 11:40
Alain Volny-Anne (France)	
Discussion	11:40 - 12:00
<i>Industry sponsored session</i>	
11:30 - 12:30	AMPHITHEATRE BLEU
Industry sponsored session	
<i>Industry sponsored session</i>	
13:00 - 14:00	AMPHITHEATRE BLEU
Industry sponsored session	
<i>Industry sponsored session</i>	
15:00 - 16:00	AMPHITHEATRE BLEU
Industry sponsored session	
<i>Ceremony</i>	
16:45 - 18:00	GRAND AMPHITHEATRE
Opening ceremony	
Milosz Parczewski (Poland)	
Karine Lacombe (France)	
Jean-Michel Molina (France)	
Bruno Spire (France)	
Welcome & Introduction	16:45 - 17:05
Milosz Parczewski (Poland)	
Karine Lacombe (France)	
Bruno Spire (France)	
Jean-Michel Molina (France)	
Welcome to Paris	17:05 - 17:10
Global Health Center	17:10 - 17:20
Michel Kazatchkine (Switzerland)	
Public Health Department of the City of Paris	17:20 - 17:30
Eve Plenel (France)	
Declaration EACS 2025 Paris	17:30 - 17:35
Caroline Andoum (France)	
EACS award	17:35 - 17:50
Peter Reiss (The Netherlands)	
Ceremony Conclusion	17:50 - 18:00
Karine Lacombe (France)	

Thursday, October 16, 2025

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP01- From Diagnosis to Retention

Sophie Grabar (France)

- | | | |
|---------|--|---------------|
| MeP01.1 | Trends in late diagnosis of HIV and its association with education and income: a nationwide cohort study from 2003 to 2023 in Sweden
Sara Falk (Sweden) | 12:05 - 12:10 |
| MeP01.2 | Factors associated with loss to follow-up among PWH-1: Analysis through linkage of the ANRS PRIMO, CODEX, and COPANA to the ANRS CO4 FHDH: the PDVCOH study
Charlène Mafuta (France) | 12:10 - 12:15 |
| MeP01.3 | Personalized dynamic predictions of the time-to-next visit: identifying individuals more prone to disengage from care
Giota Touloumi (Greece) | 12:15 - 12:20 |
| MeP01.4 | Understanding drivers of HIV-related stigma in Romanian healthcare settings
OANA MIHAELA INESCU (Romania) | 12:20 - 12:25 |

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP05 - Triple therapy forever

Silvia Nozza (Italy)

- | | | |
|---------|--|---------------|
| MeP05.1 | Real-World Effectiveness of Bictegravir- versus Dolutegravir-Based Triple regimens in High-Viremia HIV Infection: The BicDol Study
Antoine Chéret (France) | 14:05 - 14:05 |
| MeP05.2 | Long-term viral suppression, and cardiometabolic benefits of switch to ainovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study
Hong Qin (China) | 14:05 - 14:05 |
| MeP05.3 | Five-year extended follow-up of the observational BICSTaR cohort: Final analysis in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice
Benoit Trottier (Canada) | 14:05 - 14:05 |
| MeP05.4 | ART persistence among treatment-experienced people with HIV and mental health disorders in the US
James Jarrett (United Kingdom) | 14:05 - 14:05 |

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP09 - From bench to community: New evidence shaping the future of HIV treatment and prevention

Juan Ambrosioni (Spain)

- | | | |
|------------|--|---------------|
| MeP09.1.LB | Q4ddPCR Enhances Specificity in HIV Reservoir Quantification and Predicts Inducible Reservoir Size
Rachel Scheck (United States) | 15:35 - 15:40 |
| MeP09.3.LB | Impact of doxycycline adherence on bacterial STI incidence in the ANRS 174 DOXYVAC trial
Lauriane Goldwirt (France) | 15:40 - 15:45 |

MeP09.4.LB	High Risk of Renal Complications After Type 2 Diabetes Mellitus Diagnosis in People with HIV Compared with People Without HIV: Findings From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Isabela Killander Möller (Sweden)	15:45 - 15:50
MeP09.5.LB	'Ask Us' Europe, a community co-produced study: PLWH perspectives on treatment optimisation discussions with healthcare providers in 18 countries- an interim analysis Megan Devonald (United Kingdom)	15:50 - 15:55
MeP09.6.LB	Generic lenacapavir HIV pre-exposure prophylaxis could be produced for \$25 per person per year Cassandra Fairhead (United Kingdom)	15:55 - 16:00
MeP09.7.LB	PrEP cascade and HIV prevention methods preference amongst migrant women: Comparison between undocumented migrants, asylum seekers, refugees, naturalised citizens/documentated residents, and their sex work engagement status in 11 European countries, June-July, 2025 Haoyi Wang (The Netherlands)	16:00 - 16:05

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP02 - Biomarkers and Inflammation

Casper Rokx (The Netherlands)

MeP02.1	Temporal multi-omics approach in well treated PHIV youth and healthy controls: insights into soluble factors that could lead to accelerated inflammaging Julie van der Post (The Netherlands)	12:05 - 12:10
MeP02.2	Exploring Impact of Inflammation and Body Composition on Frailty Dynamics Among Older People with HIV Win Min Han (Thailand)	12:10 - 12:15
MeP02.4	Neurocognitive and Plasma Biomarker Changes Following Antiretroviral Therapy Initiation in Treatment-Naïve People Living with HIV: A Prospective 18-Month Study Charalampos D. Moschopoulos (Greece)	12:15 - 12:20
MeP02.5	Metformin prevents weight gain in non-diabetic adults with HIV: results from a randomized, placebo-controlled trial Cristina Marcelo Calvo (Spain)	12:20 - 12:25

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP06 - Sex, bugs and prevention

Gilles Wandeler (Switzerland)

MeP06.1	The Impact of 4CMenB Vaccination and Doxycycline post-exposure prophylaxis on Pharyngeal Meningococcal Carriage among MSM using HIV PrEP Ala-Eddine Deghmane (France)	14:05 - 14:10
MeP06.2	Pharmacokinetics and efficacy of a single dose of 200 mg of doxycycline in men who have sex with men using PrEP Lauriane Goldwirt (France)	14:10 - 14:15
MeP06.3	Modeling DoxyPEP impact amongst PrEP users: an opportunity for prevention in low-middle income countries Mariana Ariadna Paolini (Argentina)	14:15 - 14:20
MeP06.4	Risk Factors Associated with Bacterial Sexually Transmitted	14:20 - 14:25

Infections (STIs) Among Men Who Have Sex with Men (MSM) During the Pre-Exposure Prophylaxis (PrEP) era: a Systematic Review and Meta-Analysis in High-Income Countries

Mathieu Castry (France)

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP10 - Drug-resistance and defective virus

Silvia Nozza (Italy)

- | | | |
|------------|--|---------------|
| MeP10.1 | Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study
A. Yin Edwards (United States) | 15:35 - 15:40 |
| MeP10.2 | High <i>in vitro</i> resistance barrier for the bictegavir/lenacapavir combination
Michelle L. D'Antoni (United States) | 15:40 - 15:45 |
| MeP10.3 | Genotypic susceptibility to broadly neutralizing antibodies and fostemsavir of transmitted viruses, and evolution over time in the French acute HIV infection PRIMO cohort
Hegger Machado Fritsch (France) | 15:45 - 15:50 |
| MeP10.4 | Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial
Jose Arribas (Spain) | 15:50 - 15:55 |
| MeP10.5 | How Should APOBEC3-induced Resistance Mutations be Considered in the Management of Antiretroviral Therapy?
Marie Gilbert (France) | 15:55 - 16:00 |
| MeP10.6 | Nucleocapsid mutations at time of virological failure with an integrase inhibitor
Quentin Le Hingrat (France) | 16:00 - 16:05 |
| MeP10.7.LB | Virological success with long-acting cabotegravir and rilpivirine in individuals with historical rilpivirine resistance: a real-world case series
Félix Gutiérrez Rodero (Spain) | 16:05 - 16:10 |

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP03 - Sexual health among people living with HIV

Robert Hejzák (Czech Republic)

- | | | |
|------------|---|---------------|
| MeP03.1 | Sexual Dissatisfaction in People Living With HIV, results from the Vive+ project
Beatriz Julieta Blanco Rojas (Spain) | 12:05 - 12:10 |
| MeP03.2.LB | Educational Needs Assessment on HIV Prevention and PrEP Knowledge among People who Are Trans and Non-Binary in Europe

Paulie "Amanita" Calderón-Cifuentes (Germany) | 12:10 - 12:15 |
| MeP03.3 | From Pilot to Practice: Strengthening Sexual Health Care Counseling in HIV clinical practice through Education and Training
Suzanne de Munnik (The Netherlands) | 12:15 - 12:20 |
| MeP03.4 | "I didn't think it was serious": understanding sexual dysfunction care needs of gay, bisexual and other men who have sex with men | 12:20 - 12:25 |

living with HIV in Montreal, Canada

Bertrand Lebouché (Canada)

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP07 - How to optimize patient-provider relationship: stigma and understanding

Robert Hejzák (Czech Republic)

- | | | |
|---------|--|---------------|
| MeP07.1 | Developing, delivering and evaluating a bespoke HIV Knowledge and Stigma training program for healthcare workers; changes in knowledge and attitudes towards people with HIV
Linda Cheyenne Vaccari (United Kingdom) | 14:05 - 14:10 |
| MeP07.2 | HIV-RELATED STIGMA AND DISCRIMINATION AMONGST HEALTH CARE PROVIDERS IN ARGENTINA: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY
José A. E. Barletta (Argentina) | 14:10 - 14:15 |
| MeP07.3 | Implementation of Mobile Clinics in Ukraine During Wartime: Early Outcomes of a Nationwide Program
Svitlana Vynohradova (Ukraine) | 14:15 - 14:20 |
| MeP07.4 | Structural factors associated with viral suppression among transgender women living with HIV in France, ANRS-Trans&HIV: a nationwide retrospective life-event survey
Margot Annequin (France) | 14:20 - 14:25 |

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP11 - Cardiovascular and metabolic diseases

Casper Rokx (The Netherlands)

- | | | |
|---------|--|---------------|
| MeP11.1 | HIV infection is strongly associated with acute myocardial infarction, independently of age, gender, and comorbidities: a population-based cohort study
Robert Güerri-Fernández (Spain) | 15:35 - 15:40 |
| MeP11.2 | Systolic inter-arm blood pressure difference and coronary artery disease in people with HIV
Sávio Amaral (Brazil) | 15:40 - 15:45 |
| MeP11.3 | Healthcare Utilization and Costs in People Living with HIV With and Without Hypertension and Type 2 Diabetes Mellitus in the United States
Sean P. Fleming (United States) | 15:45 - 15:50 |
| MeP11.4 | Rethinking obesity: applying the Lancet Commission framework on clinical obesity to people living with HIV in South Africa
Joana Woods (South Africa) | 15:50 - 15:55 |
| MeP11.5 | Comparable gut microbiome composition and diversity in people living with HIV with and without metabolic dysfunction-associated steatotic liver disease
Magnus Søltøft Lindhardt (Denmark) | 15:55 - 16:00 |
| MeP11.6 | Prevalence and associated risk factors for MASLD in people living with HIV: highlighting metabolic syndrome components
Adrian Rodriguez (Spain) | 16:00 - 16:05 |
| MeP11.7 | Prevalence of Addictive behaviours in MSM practicing Chemsex, and impact on their sexuality: results of the PACmen study
Thomas L'yavanc (France) | 16:05 - 16:10 |

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP04 - Antiviral drugs: viral escape and immunological failure

Antonella Castagna (Italy)

- | | | |
|---------|---|---------------|
| MeP04.1 | HIV persistence in deep tissues on dolutegravir based antiretroviral therapy is not associated with the selection of drug resistance mutations to second generation INSTI (ANRS DOLUVOIR)
Gilbert Mchantaf (France) | 12:05 - 12:10 |
| MeP04.2 | HIV-1 cell-to-cell Transmission to macrophages escapes type I interferon and host restriction factors, and is resistant to antiretroviral drugs
Sen Yan (France) | 12:10 - 12:15 |
| MeP04.3 | DOLUTEGRAVIR IMPACT IN CARDIOVASCULAR GENES USING ZEBRAFISH EMBRYO MODEL
Giorgio Tiecco (Italy) | 12:15 - 12:20 |
| MeP04.4 | Dysregulated Neutrophil Apoptosis and Emergence of Inflammatory Subsets in people living with HIV: Mechanisms of Immunological Failure
Aiwei Zhu (China) | 12:20 - 12:25 |

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP08 - Pregnancy, children and adolescents

Nicolas Nagot (France)

- | | | |
|---------|--|---------------|
| MeP08.1 | Socio-demographic and socio-economic characteristics of women diagnosed with HIV during the pregnancy, using registry data from Statistic Netherlands
Colette Smit (The Netherlands) | 14:05 - 14:10 |
| MeP08.2 | Breastfeeding and HIV in High-Income Settings: Exploring Women living with HIV and Health-care Providers' Perspectives in Belgium
H'ava Masquelier (Belgium) | 14:10 - 14:15 |
| MeP08.3 | Semi-structured interviews with women living with HIV and their health care professionals to determine factors influencing counseling on infant feeding options: a qualitative study
Lena van der Wekken-Pas (The Netherlands) | 14:15 - 14:20 |
| MeP08.4 | Transition experiences of young adults with perinatal HIV in the Netherlands
Annouschka Weijzenfeld (The Netherlands) | 14:20 - 14:25 |

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP12 - Co-infections and vaccination

Gilles Wandeler (Switzerland)

- | | | |
|---------|--|---------------|
| MeP12.1 | Prevalence, Incidence, and Clearance of Anal HPV Infection Among MSM in Japan: A Longitudinal Cohort Study
Naokatsu Ando (Japan) | 15:35 - 15:40 |
| MeP12.2 | The Impact of COVID-19 on HIV Care Disruption and Return to Treatment in Mauritius: Findings from the COVIH-OI Qualitative Study
Kenny Emmanuel Eleonore (Mauritius) | 15:40 - 15:45 |
| MeP12.3 | A case series of acute hepatitis B among PLWH switched to long acting (LA) Cabotegravir (CAB)/ Rilpivirine (RPV)
Sophie Seang (France) | 15:45 - 15:50 |

MeP12.4	Prevalence and Factors Associated with Liver Cirrhosis in People with HIV and Chronic Hepatitis B: A Cross-sectional Study in Spain, Germany, and Poland Juan Berenguer (Spain)	15:50 - 15:55
MeP12.5	Understanding why modelling studies by the Center for Disease Analysis Foundation fail to provide reliable estimates of Hepatitis C prevalence in Northern and Western Europe Barbara Bertisch (Switzerland)	15:55 - 16:00
MeP12.6	Significantly More HIV-Seropositive Adults(PLWHA) Lack Detectable Anti-Measles IgG After Childhood Measles, Mumps, Rubella (MMR) Vaccinations When Compared to HIV-Seronegative Controls Gary Blick (United States)	16:00 - 16:05
MeP12.7	Impact of Antimicrobial Prophylaxis on AIDS-Defining Events in People with HIV: a Multicenter Experience Chiara Fusetti (Italy)	16:05 - 16:10
 <i>Industry sponsored session</i> 08:00 - 09:00		
Industry sponsored session		AMPHITHEATRE BLEU
 <i>Roundtable Discussion</i> 08:00 - 09:00		
RT1 - Community-based and participatory research in the field of HIV Paulie "Amanita" Calderón-Cifuentes (Germany)		AMPHITHEATRE BORDEAUX
	Roundtable Discussion on Community-based and participatory research in the field of HIV Nicolas Lorente (Spain) Grzegorz Jezierski (Poland) Perrine Roux (France)	08:00 - 09:00
 <i>Meet-the-expert</i> 08:00 - 09:00		
MTE1 - Statin guidelines implementation after REPRIEVE: one year later Esteban Martínez (Spain) Franck Boccara (France)		ROOM MAILLOT
	ESC Recommendations Franck Boccara (France)	08:00 - 08:05
	EACS Recommendations Esteban Martínez (Spain)	08:05 - 08:10
MTE1.1	Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting Rebecka Papaioannu Borjesson (Italy)	08:10 - 08:19
	Interactive discussion with the audience	08:19 - 09:00
 <i>Meet-the-expert</i> 08:00 - 09:00		
MTE2 - Tuberculosis in 2025 Nathalie De Castro (France) Daria Podlekareva (Denmark)		ROOM 242AB
MTE.C2.1	A diagnostic and therapeutic odyssey in advanced HIV: disseminated tuberculosis with hematologic and renal involvement Sabri Atalay (Turkey)	08:00 - 08:09

MTE.C2.2	Use of anakinra for corticosteroid-refractory paradoxical IRIS in patients with HIV and tuberculous lymphadenitis: two case reports Alberto Díaz-de Santiago (Spain)	08:09 - 08:18
MTE.C2.3	The case of cutaneous TB in person living with HIV from Eastern European country of Georgia Shorena DVALI (Georgia)	08:18 - 08:27
	Interactive discussion with the audience	08:27 - 08:57
<i>ePosters</i> 09:00 - 18:00		ePoster Exhibition
ePosters on Display		
	A. Basic and Translational Science	09:00 - 09:00
eP001	Refining the resistance landscape of lenacapavir in HIV-1 through cell-based selection Jolieke A. T. van Osch (The Netherlands)	09:00 - 09:00
eP002	Dasatinib enhances innate macrophage restriction and limits HIV-1 replication Clara Sánchez Menéndez (Spain)	09:00 - 09:00
eP003	HIV persistence in cisgender women after long periods on ART: could be shaped by the route and moment of HIV acquisition? Lucia Baquero (Argentina)	09:00 - 09:00
eP004	HIV-specific CD8+ T-cell response drives viral selection and integration site in silent regions in individuals treated during the acute phase of HIV acquisition Pien van Paassen (The Netherlands)	09:00 - 09:00
eP005	HIV-specific T-cell immune response in elite controllers Lucia Baquero (Argentina)	09:00 - 09:00
eP006	Linking Gut Microbiome to HIV Reservoir Size in People Living with HIV Oscar Kieri (Sweden)	09:00 - 09:00
eP007	Longitudinal dynamics of virology, immunity, and HIV-1 reservoir in people living with HIV and cancer: impact of antitumor therapy and immune checkpoint inhibitors Jingchun Mao (China)	09:00 - 09:00
eP008	Machine learning identified genetic features associated with HIV Sequences in the Monocytes Xiaorong Peng (China)	09:00 - 09:00
eP009	Variations in sero-biomarkers of gut barrier dysfunction and sCD14 in ART-naïve PWH initiating ART Valentina Iannone (Italy)	09:00 - 09:00
eP010	Decoding HIV: two technologies, one genome Nadia Randazzo (Italy)	09:00 - 09:00
eP011	False Positivity in HIV Screening Using Fourth-Generation Assay: Performance and Potential Influencing Factors in a Low Prevalence Population Lily Shui-kuen Cheng (Hong Kong)	09:00 - 09:00
eP012	Feasibility and reliability of decentralized HIV-1 viral load monitoring on self-sampled blood Kyra Mendes de Leon (The Netherlands)	09:00 - 09:00

eP013	Limited performance of FIB-4 and NAFLD fibrosis score for detecting liver fibrosis in people living with HIV Ahmed Cordie (Egypt)	09:00 - 09:00
eP014	Whole-genome sequencing for HIV-1 drug resistance testing: are we ready? Federica Stefanelli (Italy)	09:00 - 09:00
eP015	Dynamic Crosstalk Between MAIT Cells and NK Cells in Incomplete Immune Reconstitution of Individuals acquiring HIV Zhuoya Deng (China)	09:00 - 09:00
eP016	Dynamics and Immunological Signature of $\gamma\delta$ T Cells Following Antiretroviral Therapy Initiation in Acute HIV-1 Infection Zhen Li (China)	09:00 - 09:00
eP017	Extracellular Acyl-CoA-Binding Protein prevents autophagy and T-cell function in people with HIV Stephane Isnard (Canada)	09:00 - 09:00
eP018	Immune checkpoint patterns in cerebrospinal fluid after ART initiation related to neurocognitive decline among PWH ANA JOY LOZANO (Philippines)	09:00 - 09:00
eP019	Modulation of TLR-Driven Monocyte Activation by JAK-STAT Inhibitors in People With HIV Marion Camard (France)	09:00 - 09:00
eP020	Reduction of immune- senescence in People with HIV (PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine Mariasilvia Guardiani (Italy)	09:00 - 09:00
eP021	Tenascin-C Bridges Biomarker Discovery and Immune Modulation in Incomplete Immune Reconstitution Among People Living with HIV Zhuoya Deng (China)	09:00 - 09:00
eP022	Type I Interferon Drives Myeloid-Mediated T-Cell Activation in People Living with HIV Under Antiretroviral Therapy Léo Plaçais (France)	09:00 - 09:00
eP023	ANTIOXIDANT CAPACITY IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY Radoslava Emilova (Bulgaria)	09:00 - 09:00
eP024	Differential expression of ER-TR7 following challenge with more recent antiretroviral drugs: an <i>in vitro</i> model Maria Aurora Carleo (Italy)	09:00 - 09:00
eP026	Functional characterization of the HIV-2 V3 loop: Insights into host interaction and viral tropism Paloma Gonçalves (Portugal)	09:00 - 09:00
eP027	High levels of anti-HHV-8 IgG binding capacity are linked with low HHV-8 viremia in people with and without HIV Stephane Isnard (Canada)	09:00 - 09:00
eP028	Identification of transcriptional active SIV-infected cells in Rhesus Macaques Jerome Estaquier (Canada)	09:00 - 09:00
eP029	Impaired Immune Reconstitution in PLWH: the Role of CD4⁺T-Cell-Associated NKG2D Ligands and CD4⁺T-Cell Subsets Imbalance Peng Xu (China)	09:00 - 09:00

eP030	Markers of astroglial/monocyte activation and inflammation are associated with neurocognitive impairment in people with HIV on suppressive ART Matteo Augello (Italy)	09:00 - 09:00
eP031	Microglia cause HIV-induced transcriptional and metabolomic changes in human brain organoids leading to neurological impairment Pamela E. Capendale (The Netherlands)	09:00 - 09:00
eP032	Myeloid production of the mitokine GDF15 is associated with HIV reservoir size and non-AIDS comorbidity marker in ART-treated people with HIV Stephane Isnard (Canada)	09:00 - 09:00
eP033	Single-Cell Transcriptomic Analysis Reveals Nef-Induced Dysregulation of Hematopoietic Stem Cell Development and Aging-Associated Pathways in HIV Infection Wei Zou (China)	09:00 - 09:00
eP034	A Systematic Analysis of Immune Responses Following BCG Vaccination in People with HIV Johannes Nemeth (Switzerland)	09:00 - 09:00
eP035	Optimized Expression of CD4-Inducible (CD4i) Epitopes in HIV-1 Vaccine Prototypes Based on Virus-Like Particles (VLPs) ALMUDENA RUBIO-PEREZ (Spain)	09:00 - 09:00
eP036	Development of diagnostic/prognostic marker and therapeutic target for HCV-mono- and HIV/HCV-co-infection-mediated liver diseases IN-WOO PARK (United States)	09:00 - 09:00
eP037	Low-level viraemia (LLV) in people living with HIV and its management at an HIV centre in London Matthew Valentino (Malta)	09:00 - 09:00
eP038	Novel NGS-based Pipeline for HIV-1 pol Region Analysis Arina Syrkina (Russian Federation)	09:00 - 09:00
eP039	Proviral DNA genotyping among patients living with HIV with Undetectable Viral Load or Low-Level Viral Load Dan Turner (Israel)	09:00 - 09:00
eP040	Exploration of the genetic diversity and the evolution of HIV-1 non-B subtypes in Serbia: phylogenetic information beyond viral spread Marina Siljic (Serbia)	09:00 - 09:00
eP041	Using Nanopore sequence data to analyse drug resistance profile and its association with phylodynamics from HIV quasispecies Tsz Ho Kwan (Hong Kong)	09:00 - 09:00
	B1. Clinical Science - Antiretroviral therapy	09:00 - 09:00
eP042	A Clinical Pathway for the Use of Long-Acting Injectable antiretroviral therapy (LAI-ART) in Adherence Challenged People Living with HIV Siobhan Quirke (Ireland)	09:00 - 09:00
eP043	A combined dolutegravir-rilpivirine oral regimen as lead-in therapy for long-acting injectable antiretroviral treatment in people living with HIV Mayda Rahi (France)	09:00 - 09:00
eP044	Adverse events and treatment discontinuation in a large, observational cohort of PLHIV starting Dolutegravir or non-	09:00 - 09:00

	Dolutegravir-based antiretroviral therapy (ART) in Brazil: The CODE cohort Carlos Brites (Brazil)	
eP045	Analysis of viral load and INSTI resistance in people with HIV-1A6 receiving oral second generation INSTI Maarten van de Klundert (Sweden)	09:00 - 09:00
eP046	Antiviral exposure and risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Magnus Søltøft Lindhardt (Denmark)	09:00 - 09:00
eP047	B/F/TAF in Latin American Elderly PLWH: A 96-Week Analysis of Effectiveness, Safety, and Metabolic Outcomes from the BICTARG Cohort Cinthia Lamaizon (Argentina)	09:00 - 09:00
eP048	Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV Aged ≥50: Low Discontinuation Rates and Favorable Metabolic Outcomes Over 36 Months Andrea De Vito (Italy)	09:00 - 09:00
eP049	CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France Patrick Philibert (France)	09:00 - 09:00
eP050	Changes in Neuronal Injury and Inflammation Biomarkers in CSF of People Switching to Doravirine plus Raltegravir Analuz Fernández (Spain)	09:00 - 09:00
eP051	CHANGES IN QUALITY OF LIFE IN PEOPLE LIVING WITH HIV SWITCHING TO DOLUTEGRAVIR-BASED REGIMENS, FROM STABLE OR FAILING CURRENT ANTIRETROVIRAL REGIMENS IN THE CODE COHORT Liliane Lins-Kusterer (Brazil)	09:00 - 09:00
eP052	Changes in weight and BMI associated with switching to doravirine/lamivudine/tenofovir disoproxil fumarate vs. continuing an integrase inhibitor- or protease inhibitor-based regimen- an observational prospective case-control study Charlotte-Paige Rolle (United States)	09:00 - 09:00
eP053	Characteristics and Outcomes of People with HIV (PWH) Virologically Suppressed on Complex Regimens Richard Elion (United States)	09:00 - 09:00
eP054	Clinical and immunovirological outcomes in advanced people living with HIV receiving dual versus triple drug regimens: a real-world cohort study Emanuela Zappulo (Italy)	09:00 - 09:00
eP055	Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2-drug or continuing 3-drug therapy over 18-months of follow-up Lia Fiaschi (Italy)	09:00 - 09:00
eP056	Comparative Dynamics of Inflammatory Biomarkers in Antiretroviral-Naïve MSM with HIV initiating DTG/3TC versus BIC/FTC/TAF Ran Wang (China)	09:00 - 09:00
eP057	Comparison of HIV diagnosis and treatment features in cis- and trans-gender women in two different European Centres (London	09:00 - 09:00

	and Padua) Maria Mazzitelli (Italy)	
eP058	COMPARISON OF THE RESPONSE TO ANTIRETROVIRAL TREATMENT BETWEEN LATE PRESENTING AND OTHER ADULT PEOPLE LIVING WITH HIV: A 13- YEAR SINGLE-CENTER EXPERIENCE Figen Kaptan Aydoğmuş (Turkey)	09:00 - 09:00
eP059	Differences on Clinical and Virological Outcomes of Cabotegravir + Rilpivirine Long Acting between Men and Women in the Dat'AIDS Cohort Clotilde Allavena (France)	09:00 - 09:00
eP060	Discontinuations of long-acting injectable cabotegravir and rilpivirine in observational cohorts Chloe Pasin (United Kingdom)	09:00 - 09:00
eP061	Does adherence to CAB + RPV decrease over time in real world? A substudy from the RELATIVITY cohort Luis Buzon Martín (Spain)	09:00 - 09:00
eP062	DOLAM-500: 48 and 96-Week Real-World Efficacy and Safety of Dolutegravir Plus Lamivudine in ART-Naïve Individuals with Baseline HIV-1 RNA $\geq 500,000$ copies/mL Asuman İnan (Turkey)	09:00 - 09:00
eP063	DOLANKA: Real World Data on the use of two drug regimen Dolutegravir (DTG) + Lamivudine (3TC) in treatment-naïve people living with HIV in Ankara-Turkey: Interim analysis results MELIHA CAGLA SONMEZER (Turkey)	09:00 - 09:00
eP064	DTG/3TC AS INITIAL THERAPY IN PEOPLE LIVING WITH HIV AND VIRAL LOAD $> 500,000$ COPIES/ML AND CD4 CELL COUNT $\geq 200/mm^3$ Juan Martin-Torres (Spain)	09:00 - 09:00
eP066	Durability and reasons for treatment discontinuation of BIC/FTC/TAF in real life: data from 927 Persons With HIV in charge to "D. Cotugno" hospital, Naples, Southern Italy Francesco Maria Fusco (Italy)	09:00 - 09:00
eP067	Durability of long-acting cabotegravir + rilpivirine in virologically suppressed adults living with HIV: a multicenter observational study in Tuscany (LAHIV) Giuseppe Gasparro (Italy)	09:00 - 09:00
eP068	Durability of viral suppression following antiretroviral therapy optimization to TLD among treatment-experienced adults living with HIV in Tajikistan Aziz Nabidzhonov (Tajikistan)	09:00 - 09:00
eP069	Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV TR cohort Halis Akalın (Turkey)	09:00 - 09:00
eP070	Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide from NNRTI-based ART in virologically suppressed people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH study) Andrea Antinori (Italy)	09:00 - 09:00
eP071	Epidemiological situation of HIV treatment in Tunisia, 2024 Arwa Neffati (Tunisia)	09:00 - 09:00
eP072	Equal risk of confirmed virological failure among individuals using	09:00 - 09:00

	long-acting injectable cabotegravir/rilpivirine during first and second year of follow-up: results from the Dutch ATHENA national observational cohort	
	Ferdinand W. N. M. Wit (The Netherlands)	
eP073	High Uptake of Intermittent Drug-Reduced ART Strategies Among Virally Suppressed People Living with HIV (PWH) at an HIV Clinic in Paris, France	09:00 - 09:00
	Christine Katlama (France)	
eP074	HIV-2: Viraemias in the course of untreated and treated "People Living With HIV-2" (PLWH2) in an observational cohort ("H2O") from Hamburg	09:00 - 09:00
	Dirk Berzow (Germany)	
eP075	Impact of Antiretroviral Therapy (ART) Regimen Initiation or Switch in Virologically Suppressed People With Human Immunodeficiency Virus-1 (HIV-1) on Lipid Profile at 48 weeks: A Systematic Literature Review	09:00 - 09:00
	Julián Olalla (Spain)	
eP076	Impact of bictegravir/emtricitabin/tenofovir alafenamid (BIC/TAF/FTC) and Dolutegravir/Lamivudine on Depression Symptoms in People Living with HIV: A Retrospective Analysis of Beck Depression Inventory Scores	09:00 - 09:00
	Oguz Karabay (Turkey)	
eP077	Impact of nucleoside reverse transcriptase inhibitor resistance-associated mutations on long-term virologic suppression of bictegravir/emtricitabine/tenofovir alafenamide: real-world evidence	09:00 - 09:00
	Cinthia Lamaizon (Argentina)	
eP078	IMPACT OF PREEXISTING K103N ON THE EFFECTIVINES OF LA-CAB+RPV: REAL-LIFE RELATIVITY COHORT	09:00 - 09:00
	Luz Martín Carbonero (Spain)	
eP080	Implementation of a same-day ART start model in a real-life setting in Italy	09:00 - 09:00
	Giulia Micheli (Italy)	
eP081	Implementation Outcomes and Preliminary Effectiveness of Digitally Administering an Electronic Patient-Reported Outcome Measure of Barriers to Adherence to Antiretrovirals (the I-Score) in HIV Care	09:00 - 09:00
	David LESSARD (Canada)	
eP082	Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohoLART Study	09:00 - 09:00
	Gabriele Loi (Italy)	
eP083	Living with HIV-2: Clinical and Therapeutic Profile of a Cohort Followed in a Portuguese Local Health Unit	09:00 - 09:00
	Diana Briosa Reis (Portugal)	
eP084	Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV	09:00 - 09:00
	Júlia Calvo (Spain)	
eP085	Long-Acting CAB + RPV: Safety, Efficacy, and Discontinuation Risks in ODOACRE Cohort	09:00 - 09:00
	Andrea De Vito (Italy)	
eP086	Long-Acting Cabotegravir-Rilpivirine in Real-Life: Sex-based Characteristics and Effectiveness	09:00 - 09:00
	Ana González-Cordón (Spain)	

eP087	Long-Acting Cabotegravir-Rilpivirine in Vulnerable Population: Chemsex Practices-based Analysis Maria Martínez-Rebollar (Spain)	09:00 - 09:00
eP088	Long-Acting HIV Treatment in Practice: Promising Outcomes and Real-World Challenges from the CACTUZ Cohort Caroline Matthys (Belgium)	09:00 - 09:00
eP089	Long-acting injectable cabotegravir and rilpivirine outcomes in HIV individuals with stable treatment with dolutegravir and rilpivirine María José Galindo Puerto (Spain)	09:00 - 09:00
eP090	LONG-TERM BIC/TAF/FTC DURABILITY AND IMPACT OF DTG/3TC OR LONG-ACTING CABO/RPV Ana Moreno Zamora (Spain)	09:00 - 09:00
eP091	Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC Study Alessandro Tavelli (Italy)	09:00 - 09:00
eP092	Long-Term Metabolic and Safety Profiles of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in HIV Treatment: A Multicenter Retrospective Study Using Mixed-Effects Modeling Oguz Karabay (Turkey)	09:00 - 09:00
eP093	Modulation of biomarkers of CNS inflammation, immune activation and neuronal injury in PWH switching to long-acting injectable cabotegravir/rilpivirine therapy: 12 months of follow-up Maria Antonella Zingaropoli (Italy)	09:00 - 09:00
eP094	One-Year Clinical Outcomes of Second-generation Integrase Inhibitors Therapy in Late HIV Presenters in Egypt and Saudi Arabia Hanan Hamdy (Egypt)	09:00 - 09:00
eP095	Patient Reported Experiences and perceived benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis Eva Fernvik (Sweden)	09:00 - 09:00
eP096	Patient-Reported Health and Virological Outcomes Among People with HIV Switching to Long-Acting Injectable Cabotegravir and Rilpivirine (LANTERN) CHIEN-YU Cheng (Taiwan)	09:00 - 09:00
eP097	Patient-Reported Outcomes and Experiences in a Diverse HIV Cohort Initiating Rapid B/F/TAF: The ASAP Study Dominic Chu (Canada)	09:00 - 09:00
eP098	Profile of comorbidities in individuals who are receiving Long-Acting Cabotegravir and Rilpivirine: Real-World Insights from the RELATIVITY Cohort María José Galindo Puerto (Spain)	09:00 - 09:00
eP099	Real life data of people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide with baseline CD4+ count below 200 cells/mL (BicAdvance study) Laura Comi (Italy)	09:00 - 09:00
eP100	Real life experience with doravirine-based treatment: therapeutic efficacy and influence on lipid and T-cell immune profile Giorgio Giannetta (Italy)	09:00 - 09:00
eP101	Real world use of lenacapavir in France: a national, observational	09:00 - 09:00

	study	
	Romain Palich (France)	
eP102	Real-Life Effectiveness, Safety, and Patient-Reported Outcomes of Long-Acting Cabotegravir-Rilpivirine: Results from a large single center cohort	09:00 - 09:00
	Ana González-Cordón (Spain)	
eP103	Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence	09:00 - 09:00
	Chloe Orkin (United Kingdom)	
eP104	Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The "AReTi" Study Results	09:00 - 09:00
	Dimitrios Athanasopoulos (Greece)	
eP105	Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations	09:00 - 09:00
	Chloe Pasin (United Kingdom)	
eP106	Real-world utilization of cabotegravir/rilpivirine long-acting injectable: an observational analysis of adherence and persistence using a patient support program in Canada	09:00 - 09:00
	Jean-Francois Fortin (Canada)	
eP107	Reasons for switching to long-acting injectable antiretroviral therapy with cabotegravir/rilpivirine among adult people living with HIV: the real-life PANTER study	09:00 - 09:00
	Martin Duracinsky (France)	
eP108	Results at month 12 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every two months in viral suppressed people with HIV (PWH)	09:00 - 09:00
	Carmen Hidalgo Tenorio (Spain)	
eP109	Risk of virological failure after switch to a tenofovir-sparing dual therapy in virologically suppressed people with HIV and past HBV infection	09:00 - 09:00
	Alberto Borghetti (Italy)	
eP110	Risk of virological rebound is similar in people with HIV switching to long-acting cabotegravir/rilpivirine or integrase inhibitor-based oral therapy	09:00 - 09:00
	Flavia Badalucco Ciotta (Italy)	
eP111	Subtype-Dependent Clinical and Immunological Patterns of Acute HIV-1 Acquisition: A Retrospective Analysis from Southern China	09:00 - 09:00
	Qiuyue Zhang (China)	
eP112	Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting and impact of tenofovir resistance	09:00 - 09:00
	Alain Makinson (France)	
eP113	Switching to Generic Dolutegravir: Sustained Gains in Immunity, Viral Control, and Metabolic Stability	09:00 - 09:00
	Ahmed M. Kamel (Egypt)	
eP114	Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort	09:00 - 09:00
	Arturo Ciccullo (Italy)	

eP115	The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV Maria Jesus Perez Elías (Spain)	09:00 - 09:00
eP116	The Increasing Use of Two-Drug HIV Regimens Sarah Brown (United Kingdom)	09:00 - 09:00
eP117	TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE Tuna Demirdal (Turkey)	09:00 - 09:00
eP118	Treatment switch among US Medicare beneficiaries with HIV James Jarrett (United Kingdom)	09:00 - 09:00
eP119	Trends in opportunistic diseases at antiretroviral therapy initiation, Croatia 2009-2023 Šime Zekan (Croatia)	09:00 - 09:00
eP120	Two versus three-drug Doravirine based regimens in real life: a multicentric observational study Adriana Cervo (Italy)	09:00 - 09:00
eP121	Two-year efficacy and durability of cabotegravir and rilpivirine in the SCohoLART study Camilla Muccini (Italy)	09:00 - 09:00
eP122	Unconventional DORAVIRINE antiretroviral regime: a single-center experience Francesco Giovanni Genderini (Belgium)	09:00 - 09:00
eP123	Variability in Laboratory Monitoring After Switching to Long-Acting CAB/RPV: Patterns and Associations with Virological Outcomes Maria de Lagarde Sebastian (Spain)	09:00 - 09:00
eP124	Virological Failure on Long-Acting Cabotegravir + Rilpivirine: Associated Factors and Remaining Options in the Real-World Dat'AIDS Cohort Colin Deschanvres (France)	09:00 - 09:00
eP125	7-year sustained efficacy, safety, and immunological improvement with fostemsavir-based regimens in individuals with HIV and limited treatment options Manyu Prakash (United Kingdom)	09:00 - 09:00
eP126	Comparable efficacy but greater discontinuations due to adverse events with dolutegravir-containing two-drug versus three-drug antiretroviral therapy: a systematic review and meta-analysis Nydile Ramesh (United Kingdom)	09:00 - 09:00
eP127	Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study Margaret Gartland (United States)	09:00 - 09:00
eP128	Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a bictegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens Chloe Orkin (United Kingdom)	09:00 - 09:00
eP129	Efficacy, and safety of ainoovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials	09:00 - 09:00

	Hong Qin (China)	
eP130	Efficacy, and safety of ainoovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials Hong Qin (China)	09:00 - 09:00
eP131	Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives Cassidy A Gutner (United States)	09:00 - 09:00
eP132	Impact of switching from a bictegravir- or dolutegravir-based regimen with emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine on weight and metabolic profiles: a randomized, open-label, multicenter, parallel-group trial Kensuke Minami (Japan)	09:00 - 09:00
eP133	Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results Arman Papadakis Sali (United States)	09:00 - 09:00
eP134	Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study Carlos Brites (Brazil)	09:00 - 09:00
eP135	Switch to DOR/TDF/3TC in People With Controlled HIV and history of RNA genotype M184V/I mutation: Interim Results of the DRIVE OFF-ROAD Multicenter Single-Arm Phase II trial Jean-Jacques Parienti (France)	09:00 - 09:00
eP136	Treatment outcomes in people with a late HIV diagnosis: A pooled analysis of participants with advanced HIV disease at diagnosis randomized to receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) Jürgen K Rockstroh (Germany)	09:00 - 09:00
eP137	LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT Kaddu Muhamed yahya (Uganda)	09:00 - 09:00
eP138	Physician specialties involved in prescribing BIC/F/TAF and concomitant drugs in people with HIV (PWH) in Germany: implications for potential drug to drug interaction (DDI) Guido Schäfer (Germany)	09:00 - 09:00
eP139	Virological Outcomes in People Living With HIV on INSTI-based cART Receiving Paclitaxel for Kaposi Sarcoma: A Retrospective Cohort Study Niroshan Dayalan (United Kingdom)	09:00 - 09:00
eP140	A French national real-world survey of people with multi-resistant HIV-1 viruses treated with an antiretroviral regimen including fostemsavir Charlotte Charpentier (France)	09:00 - 09:00
eP141	APOBEC-associated mutations in proviral HIV-DNA: assessing their impact on long-acting cabotegravir/rilpivirine treatment suitability Giovanni Massobrio (Italy)	09:00 - 09:00
eP142	Applications and Clinical Utility of Proviral HIV DNA Resistance Testing in Routine Practice: A Real-World Analysis Neva Braccialarghe (Italy)	09:00 - 09:00
eP143	Distribution of HIV-1 subtypes and genotypic resistance analysis in	09:00 - 09:00

	people living with HIV: a 9-year retrospective evaluation Aslıhan Candevir (Turkey)	
eP144	Drug resistance analysis of HIV-1 variants circulated in migrants MSM and transgender women living in Moscow, Russia in 2020-2025 Ilya Lapovok (Russian Federation)	09:00 - 09:00
eP145	Dual Validation through Trend Analysis and Spatiotemporal Profiling: A Decade-Long Roadmap for HIV Genotypic Resistance Testing Scale-Up in China's Universal Free ART Programs (2014-2023) Defu Yuan (China)	09:00 - 09:00
eP146	Durability of lenacapavir in viremic HTE PWH: real-world data from the PRESTIGIO Registry Tommaso Clemente (Italy)	09:00 - 09:00
eP147	Evidence of transmitted resistance to integrase strand transfer inhibitors (INSTIs) within local transmission clusters among antiretroviral therapy-naïve PLHIV in Greece Evangelia Georgia Kostaki (Greece)	09:00 - 09:00
eP148	Factors associated with maintenance of high CD4 counts in heavily treatment experienced multidrug resistance PWH: data from PRESTIGIO Registry Maria Santoro (Italy)	09:00 - 09:00
eP149	High virologic suppression in treatment-naïve people with HIV-1 on ainoovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study Hong Qin (China)	09:00 - 09:00
eP150	HIV Drug Resistance in People Living with HIV (PLWH) in Congo: Implications for Optimizing Therapy in Resource-Limited Settings Dominic Rauschnig (Germany)	09:00 - 09:00
eP151	HIV-1 genetic diversity and transmitted drug resistance among newly diagnosed HIV-positive individuals in Eastern European and Central Asian countries Alina Kirichenko (Russian Federation)	09:00 - 09:00
eP152	HIV-2 Drug Resistance in Portugal: NGS data from 2023-2024 Fátima Gonçalves (Portugal)	09:00 - 09:00
eP153	HIVANKA: Temporal Trends of Transmitted Drug Resistance and Subtype Distribution in Newly Diagnosed People in Ankara, Turkey (2016-2024) MELIHA CAGLA SONMEZER (Turkey)	09:00 - 09:00
eP154	Impact of PrEP on HIV-1 diversity and drug-resistance mutations in newly diagnosed HIV-1 individuals in Málaga (Southern Spain) from 2016 to 2023	09:00 - 09:00
eP155	Integrase Resistance Mutations in Treatment-Naïve Persons with Advanced Immunodeficiency Initiating Dual Therapy with Dolutegravir and Lamivudine Maria Figueroa (Argentina)	09:00 - 09:00
eP156	Potential for replacing the boosted-PI with doravirine in ART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen Laura Comi (Italy)	09:00 - 09:00
eP157	Proviral DNA as a Reliable Tool for Resistance Testing in HIV-2:	09:00 - 09:00

	Long-Term Outcomes in a Portuguese Cohort Inês Lopes (Portugal)	
eP158	Selection of antiretroviral resistance in treatment-experienced PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study Anne-Genevieve Marcelin (France)	09:00 - 09:00
eP159	Selection rate of resistance to Long-Acting CAB/RPV in a real life French cohort with strict inclusion and monitoring criteria Sidonie LAMBERT-NICLOT (France)	09:00 - 09:00
eP160	Switching to bicitegravir/emtricitabine/tenofovir alafenamide in highly treatment experienced people living with multidrug-resistant HIV Jose Luis Casado Osorio (Spain)	09:00 - 09:00
eP161	The profile of surveillance HIV resistance mutations in the migrant population of a tertiary hospital: a 4-year analysis Gonçalo Cruz (Portugal)	09:00 - 09:00
eP162	The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry Tommaso Clemente (Italy)	09:00 - 09:00
eP163	Trends of HIV drug resistance and associated factors: an analysis of the Uganda national HIV drug resistance program data, 2021-2024 Bridget Ainembabazi (Uganda)	09:00 - 09:00
eP164	CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF DORAVIRINE: IMPLICATIONS IN NEUROCOGNITIVE IMPAIRMENT Qing Ma (United States)	09:00 - 09:00
eP165	Pharmacogenetics of Dolutegravir and Bicitegravir Plasma and Intracellular Pharmacokinetics Leïla Belkhir (Belgium)	09:00 - 09:00
eP166	Pharmacokinetics and safety of MK-8527 in adults with moderate or severe renal impairment Jesse C. Nussbaum (United States)	09:00 - 09:00
eP167	Real-life switch to long-acting cabotegravir/rilpivirine ensures adequate drug levels without short-term impact on viral reservoir or inflammation: the Long-Icna study Antonella d'Arminio Monforte (Italy)	09:00 - 09:00
eP168	An audit of antiretroviral regimens in people living with HIV attending an HIV/sexual health clinic in Sydney's Inner West in response to the REPRIEVE study Rachel Burdon (Australia)	09:00 - 09:00
eP169	Effect of dolutegravir transition in HIV-positive adults at a university-based tertiary care hospital in Thailand Rujipas Sirijatuphat (Thailand)	09:00 - 09:00
eP170	Safety and durability of treatment with Bicitegravir/Emtricitabine/Tenofovir Alafenamide in a real-life cohort Nicola Squillace (Italy)	09:00 - 09:00
eP171	Virologic Outcomes of Dolutegravir-Based ART Among Thai people with HIV Previously Treated with Lopinavir/ritonavir based Second-line regimens: A National Program Analysis Anchalee Avihingsanon (Thailand)	09:00 - 09:00

	B2. Clinical Science - Co-infection	09:00 - 09:00
eP172	Immune correlates of protection vs vaccine hesitancy in people living with HIV: to be or not to be (vaccinated) Alejandro Vallejo (Spain)	09:00 - 09:00
eP173	Comparative Analysis of Mpox Cases in People Living with HIV in Lisbon and Rio de Janeiro During the 2022 Outbreak Raffaele Junior Aliberti (Portugal)	09:00 - 09:00
eP175	Estimating Hard-to-reach Populations in South Korea Using Mpox Mathematical Modeling Sol Kim (Korea, Republic of)	09:00 - 09:00
eP176	HIV and mpox co-infection in Israel: a cross-sectional comparative study Zohar Mor (Israel)	09:00 - 09:00
eP177	Mpox infection alters HIV-1 reservoir dynamics in ART-treated people with HIV Guiomar Casado Fernández (Spain)	09:00 - 09:00
eP178	Mpox infection elicits stronger and more sustained T-cell responses than vaccination in people with HIV and PrEP users Olivia de la Calle-Jiménez (Spain)	09:00 - 09:00
eP179	Mpox-specific humoral and cellular immune responses up to two years from natural infection or MVA-BN vaccination Valentina Mazzotta (Italy)	09:00 - 09:00
eP180	Asymptomatic CMV Suppression with Letemovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383 John Koethe (United States)	09:00 - 09:00
eP181	Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections in People Living (PLWH) with HIV Who Engage in Chemsex: A Descriptive Ambispective Study in Barcelona Maria Martínez-Rebollar (Spain)	09:00 - 09:00
eP182	Experience using a Portable Fundus Camera to Prevention of Blindness in people living with HIV in Ukraine Maryna Sira (Ukraine)	09:00 - 09:00
eP183	Influence of a 3-month letemovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy Stephane Isnard (Canada)	09:00 - 09:00
eP184	Measles in People Living with HIV: A Comparative Analysis with HIV-Negative Patients David Valentin Mangaloiu (Romania)	09:00 - 09:00
eP185	Missed opportunities for early HIV diagnosis in people living with HIV in a Romanian tertiary care center Cristiana Oprea (Romania)	09:00 - 09:00
eP186	Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis Asta Maria Blom Nielsen (Denmark)	09:00 - 09:00
eP187	Resistance profiles and therapeutic approach of <i>Klebsiella pneumoniae</i> strains identified in people living with HIV and other hospitalized individuals Cristiana Oprea (Romania)	09:00 - 09:00

eP188	Risk of Pneumocystis Pneumonia by CD4 Level in Ukrainian Adults Living With HIV: A Retrospective Analysis Diana Shevchenko (Ukraine)	09:00 - 09:00
eP189	Severe <i>Rhodococcus equi</i> in Late Presenters With HIV: A Case Series and Therapeutic Challenges Ivana Gmizic (Serbia)	09:00 - 09:00
eP190	Systematic Review and Meta-Analysis of Human Papilloma Virus Prevalence and Geno-type Disparity among HIV-positive Women in Africa Yirga Wondu Amare (Hungary)	09:00 - 09:00
eP191	Association between plasma inflammatory profile and sexually transmitted infections recurrence in PrEP users and people with HIV Yolanda Campanero Núñez (Spain)	09:00 - 09:00
eP192	Assessing the Impact of PrEP on STI Rates: a Real-World Multicenter Cohort from Milan Donatella Maddalena (Italy)	09:00 - 09:00
eP193	Awareness and attitudes toward Doxycycline Post-Exposure Prophylaxis (DoxyPEP) among MSM in Greece: A cross-sectional study Konstantinos Protopapas (Greece)	09:00 - 09:00
eP194	Comparative effectiveness of 250 mg vs 500 mg ceftriaxone in treating uncomplicated gonorrhea in a country of a low prevalence of ceftriaxone-nonsusceptible <i>Neisseria gonorrhoeae</i> Tzong-Yow Wu (Taiwan)	09:00 - 09:00
eP195	Doxycycline prophylaxis use among MSM attending a reference center for STI and HIV treatment in Rome Alessandra Latini (Italy)	09:00 - 09:00
eP196	Prevalence of human papilloma virus in tree loci among women with various HIV status in the Kyrgyz Republic Anastasia Pokrovskaya (Russian Federation)	09:00 - 09:00
eP197	Prevalence of human papilloma virus in tree loci among women with various HIV status in the Republic of Belarus Anastasia Pokrovskaya (Russian Federation)	09:00 - 09:00
eP198	Real-world effectiveness of doxycycline Post-Exposure Prophylaxis (DoxyPEP) in at-risk MSM in Greece Konstantinos Protopapas (Greece)	09:00 - 09:00
eP199	Sexually transmitted infections at the time of HIV diagnosis in a sexual health clinic in Spain Inés Armenteros-Yeguas (Spain)	09:00 - 09:00
eP200	AIDS patients with Talaromycosis Marneffeii exhibit inflammatory activation and depletion in their peripheral blood monocytes Pengle Guo (China)	09:00 - 09:00
eP201	Antiretroviral therapy in people with HIV and TB in France: a nationwide retrospective study between 2010 and 2023 Hugo Law-Koune (France)	09:00 - 09:00
eP202	Characterisation of Cryptococcal meningitis - a 12-year retrospective study in a hospital in Lisbon, Portugal Daniel Toscano (Portugal)	09:00 - 09:00
eP203	Epidemiological and Clinical Analysis and Outcomes of Tuberculosis Co-infection Among People Living with HIV in the Turkey ClinSurv	09:00 - 09:00

	HIV Cohort: A Large Case Series Okan Derin (Turkey)	
eP204	Factors associated with positive baseline Toxoplasma Gondii IgG antibodies among people living with HIV in recent years Carlo Bieńkowski (Poland)	09:00 - 09:00
eP205	Health Outcomes of Individuals Living with HIV Affected by Chronic Neuroinfections in Sub-Saharan Africa: Early Insights from Mozambique Helena Buque (Mozambique)	09:00 - 09:00
eP206	Incidence of opportunistic infections among people living with HIV in Rwanda. Does Differentiated care delivery matters? Mariam Salim Mbwana (Tanzania)	09:00 - 09:00
eP207	Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromyces: a multicenter retrospective study Biao Zhu (China)	09:00 - 09:00
eP208	Neuromeningeal tuberculosis in eighteen PLWHIV NASSIMA BELABAS (Algeria)	09:00 - 09:00
eP209	Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated Pneumocystis Pneumonia Huan Xia (China)	09:00 - 09:00
eP210	Predictors of Recurrence and Survival in HIV-Associated Nontuberculous Mycobacterial Infections: A 20-Year Retrospective Cohort Study Johannes Zielke (Germany)	09:00 - 09:00
eP211	Dynamic Sequential Organ Failure Assessment (SOFA) Score and quick SOFA (qSOFA) predict 30-day mortality in patients with HIV-associated Talaromyces: a multicenter cohort study Guanjing Lang (China)	09:00 - 09:00
eP212	The most common nontuberculous mycobacteria species and their antibiotic resistance among people with HIV Dagny Krankowska (Poland)	09:00 - 09:00
eP213	Tuberculosis Meningitis and Other Opportunistic Infections of the Central Nervous System in Persons Living with HIV: An Observational Cohort Study in Brazil Mona Gardet (Brazil)	09:00 - 09:00
eP214	Tuberculosis profile in a cohort of people living with HIV hospitalized at the National Institute for Infectious Diseases "Prof. Dr. Matei Bals" in Bucharest, Romania Anca Negru (Romania)	09:00 - 09:00
eP215	Determinants of Influenza, HBV, and Pneumococcal Vaccination Uptake in People Living with HIV: A Multilevel and Expert Survey Study Hye Seong (Korea, Republic of)	09:00 - 09:00
eP216	Evaluating Immunization Rates in People Living with HIV based on Influenza Uptake Lee Nguyen (United States)	09:00 - 09:00
eP217	Hepatitis A and B immunization rates among MSM who are at high-risk sees potential for improvement Sven Breitschwerdt (Germany)	09:00 - 09:00
eP218	Immunity Gaps to Vaccine Preventable Diseases in People with HIV: Real-World Evidence from Japan	09:00 - 09:00

	Michiko Koga (Japan)	
eP219	Serological response to Engerix®-B vaccination in PLWHIV Rita Patrocínio de Jesus (Portugal)	09:00 - 09:00
eP220	Seropositivity and Vaccination Coverage of HBV, HAV, VZV, Measles, Rubella, and Mumps in People Living with HIV Eunmi Yang (Korea, Republic of)	09:00 - 09:00
eP221	Extracellular Vesicle DNA cargo Mirrors Systemic Immune and Microbial Perturbations in People with HIV and HCV Coinfected Individuals Sergio Grande Garcia (Spain)	09:00 - 09:00
eP222	Factors Associated with HBs Antigen Seroclearance in People Living with HIV and Chronic Hepatitis B Takashi Muramatsu (Japan)	09:00 - 09:00
eP223	Impact of intravenous methamphetamine use on Direct-acting Antiviral Agents (DAAs) treatment in people living with HIV and hepatitis C in Mexico Corazón Barrientos-Flores (Mexico)	09:00 - 09:00
eP224	Lipid dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV co-acquired clients: a retrospective study Juan Berenguer (Spain)	09:00 - 09:00
eP225	Lipidomic Profiles After HCV Cure in People with HIV Reflect Changes Linked to Significant Liver Stiffness Juan Berenguer (Spain)	09:00 - 09:00
eP226	Long-term persistence alterations in CD4 and CD8 T-cell profile after HCV elimination in people living with HIV Manuel Llamas Adán (Spain)	09:00 - 09:00
eP227	Low HCV Prevalence Among PLWH in Türkiye: Risk Factors and Treatment Gaps Bilge Caglar (Turkey)	09:00 - 09:00
eP228	Overt and Occult Hepatitis B Virus Infection among People Living with HIV/AIDS in Bulgaria Radka Komitova (Bulgaria)	09:00 - 09:00
	B3. Clinical Science - Co-morbidities and ageing	09:00 - 09:00
eP230	"The Platinum clinic", a collaborative HIV and Geriatric Medicine clinic for older people living with HIV in Dublin, Ireland Clara O'Flaherty (Ireland)	09:00 - 09:00
eP231	A Cross-Sectional Comparison of Use of Frailty Assessment Tools in Older People Living with HIV Chloe Knox (United Kingdom)	09:00 - 09:00
eP232	A retrospective review of referrals to specialist secondary care HIV-led and Gynaecology-led menopause clinics Kimberley Forbes (United Kingdom)	09:00 - 09:00
eP234	Cognitive and locomotor disorders in people living with HIV between 2007 and 2023: outcomes of the ANRS CO3 AQUIVIH-NA cohort Fabrice Bonnet (France)	09:00 - 09:00
eP235	Evaluation of a Healthy Aging Score in a Cohort of Older Adults Living with HIV in Canada Sharon Walmsley (Canada)	09:00 - 09:00

eP236	Four years frailty transitions in elderly adults living with HIV: Results from the SEPTAVIH Study Clotilde Allavena (France)	09:00 - 09:00
eP237	Frailty Screening in People Living with HIV Aged Over 65: Clinical Characteristics and Predictive Factors from a Real-World Cohort in a University Hospital in Florence, Italy Gasparro Giuseppe (Italy)	09:00 - 09:00
eP238	Gut microbiome and healthy aging in HIV: a sub-analysis of the CHANGE HIV cohort Sharon Walmsley (Canada)	09:00 - 09:00
eP239	Neurocognitive Impairment in Older People Living with HIV: Preliminary Findings from a Geriatric Care Program Liesbeth Delesie (Belgium)	09:00 - 09:00
eP240	One score to rule them all? Or maybe not quite ... Beatrice Barda (Switzerland)	09:00 - 09:00
eP241	Predicting Frailty in Older People Living with HIV Using Machine Learning Jaime Vera (United Kingdom)	09:00 - 09:00
eP242	The Prevalence and Predictors of elevated HOMA-IR in People Living with HIV (PLWH) Shu-Ying Chang (Taiwan)	09:00 - 09:00
eP243	Understanding Frailty and Aging in People Living with HIV in Kazakhstan: A Pilot Investigation Balnur Iskakova (Kazakhstan)	09:00 - 09:00
eP244	A Comparative Analysis of Echocardiographic Findings in People Living With HIV and Healthy Volunteers AYTAN SEYDALIYEVA (Turkey)	09:00 - 09:00
eP245	A Comparative Analysis of HbA1c, Glycated Albumin, and Fasting Plasma Glucose for Glycemic Assessment in People Living with HIV Tun-Chieh Chen (Taiwan)	09:00 - 09:00
eP246	A rapid scoping review of tools and approaches for medication adherence screening and assessment Nicola Galbraith (United Kingdom)	09:00 - 09:00
eP247	Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway Kate Alford (United Kingdom)	09:00 - 09:00
eP248	Association of Biomarker Clusters With Lung Disease and Mortality in People With HIV Ioannis Konstantinidis (United States)	09:00 - 09:00
eP249	Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and Incident Hypertension in People With HIV Josefine Loft (Denmark)	09:00 - 09:00
eP250	Bempedoic Acid and Evolocumab Use in People Living with HIV: A Real-World Snapshot of Lipid-Lowering Strategies in Statin-Intolerant or Reluctant individuals Marianna Menozzi (Italy)	09:00 - 09:00
eP251	Changes in Metabolic Parameters after Switching from Efavirenz to Dolutegravir-based Regimen: A Cohort Study in Thai People Living with HIV Pitchaporn Chongyanguenvong (Thailand)	09:00 - 09:00

eP252	Clinical features of transgender people living with HIV throughout Europe: multimorbidity and polypharmacy Maria Mazzitelli (Italy)	09:00 - 09:00
eP253	Confusion in the sky: to score or not to score? Beatrice Barda (Switzerland)	09:00 - 09:00
eP254	Determinants of Weight Change in HIV-Positive Individuals Receiving Antiretroviral Therapy EMİNE İLAY DUMAN (Turkey)	09:00 - 09:00
eP255	Eating habits and possible effects of Mediterranean diet on body composition in ageing people living with HIV Maria Mazzitelli (Italy)	09:00 - 09:00
eP256	Effect of extreme weight gain within 5 years in people with HIV on upcoming incident cardiovascular events Stefan Esser (Germany)	09:00 - 09:00
eP257	Effect of extreme weight gain within 5 years in people with HIV on upcoming incident diabetes mellitus Stefan Esser (Germany)	09:00 - 09:00
eP258	Effects of high-dose probiotic supplementation on immune activation and neurocognitive disorders in people living with HIV on successful antiretroviral treatment: the ProCog study Matteo Vassallo (France)	09:00 - 09:00
eP259	Enhancing Transplant Access for People with HIV: A Comparative Study of Liver and Kidney Transplant Outcomes from donors with or without HIV Adriana Cervo (Italy)	09:00 - 09:00
eP260	Epicardial adipose tissue thickness and cardiometabolic risk in people living with HIV: a comparative study of TAF- and TDF-based regimens Özge Eren Korkmaz (Turkey)	09:00 - 09:00
eP261	From wasting to gaining: The impact of BMI changes on dyslipidemia risk in people living with HIV Jisun Chung (Korea, Republic of)	09:00 - 09:00
eP262	Genetic influence of TM6SF2 rs58542926 genotype on significant liver fibrosis in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD) Win Min Han (Thailand)	09:00 - 09:00
eP263	How do people living with HIV sleep? Macha Tetart (France)	09:00 - 09:00
eP264	Hypertension in People with HIV Starting ART: Association with Regimen Class Jose I Bernardino (Spain)	09:00 - 09:00
eP265	Impact of a Mediterranean Diet-Based Nutritional Intervention on Lipid Profile in People Living with HIV: Interim Results at Week 24 from a Randomized Controlled Clinical Trial Esperanza Cañas-Ruano (Spain)	09:00 - 09:00
eP266	Implementation of FIB-4 Screening and Determinants of Liver Fibrosis Among People Living with HIV: A Real-World Cohort Study Olivier Robineau (France)	09:00 - 09:00
eP267	Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT, a	09:00 - 09:00

	randomized phase 3 trial Hong Qin (China)	
eP268	Improved body weight, lipid and immune profile and adipose tissue gene expression after a 48-week switch from an INSTI regimen to DOR/3TC/TDF in persons with HIV with INSTI-associated weight gain: The ADDORE study J Capeau (France)	09:00 - 09:00
eP269	Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort Ana Luz Cano Díaz (Mexico)	09:00 - 09:00
eP270	Incidental Detection of Gynecomastia and Adipomastia on Chest CT in Male People Living with HIV: An Opportunistic Imaging Assessment Veysel Akca (Turkey)	09:00 - 09:00
eP271	Influence of HIV status on organ procurement and allocation: A Discrete Choice Experiment among Australian Transplant Providers David WJ Griffin (Australia)	09:00 - 09:00
eP272	Insights from Gut Microbiome Profiling: <i>Evtapia spp.</i> as a Distinctive Marker of Leanness in People with HIV Mackenzie Joe (United States)	09:00 - 09:00
eP273	Longitudinal changes of coronary artery calcium score (CACS) in persons with HIV Maithili Varadarajan (United Kingdom)	09:00 - 09:00
eP274	Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to ainoovirine coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study Hong Qin (China)	09:00 - 09:00
eP275	Long-term Lipid Metabolism Benefits of Switching to Ainoovirine-based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study Hong Qin (China)	09:00 - 09:00
eP276	Medication Optimization in Older People Living with HIV: A Multidisciplinary Approach Fatma Nisa Ballı Turhan (Turkey)	09:00 - 09:00
eP277	Metabolic Liver Disease in Newly Diagnosed People Living with HIV: MASHIV-TR COHORT Mustafa Kemal Celen (Turkey)	09:00 - 09:00
eP279	Monocyte polarization is related to Atherosclerosis in People Living with HIV on Suppressive ART Javier Lozano-Gerona (United States)	09:00 - 09:00
eP280	Neurocognitive screening in people living with HIV: 5-year referral and outcomes review Tristan Barber (United Kingdom)	09:00 - 09:00
eP281	Non-linear relationships between inflammatory markers and erectile dysfunction in a group of young men living with HIV Federico Cesanelli (Italy)	09:00 - 09:00
eP282	Obesity in people living with HIV: a retrospective analysis of a cardiovascular disease risk clinic cohort Inês Pintassilgo (Portugal)	09:00 - 09:00

eP283	People with HIV at high cardiovascular risk were undertreated with statins independent of gender Maximilian Platte (Germany)	09:00 - 09:00
eP284	Physical inactivity is associated with persistent steatotic liver disease in people with HIV Eloise Magnenat (Switzerland)	09:00 - 09:00
eP285	Preserved renal function in PWH on a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT study, a randomized phase 3 trial Hong Qin (China)	09:00 - 09:00
eP286	Prevalence and Predictors of Obesity and Metabolic Syndrome in HIV-Positive Individuals: A Cross-Sectional Study from Türkiye EMİNE İLAY DUMAN (Turkey)	09:00 - 09:00
eP287	Prevalence and risk factors of liver fibrosis in metabolic associated fatty liver disease (MAFLD) among people living with HIV (PLWH) in Shanghai Wei Xu (China)	09:00 - 09:00
eP288	Prevalence of Steatotic Liver Disease Phenotypes and Clinically Significant Fibrosis Predictors Among People With HIV in The Middle East Region: A Multicenter Study Ahmed Cordie (Egypt)	09:00 - 09:00
eP289	Progressive Pulmonary Artery Enlargement in Aging, Virologically Suppressed People With HIV: A 7-Year CT Imaging Study Napon Hiranburana (Thailand)	09:00 - 09:00
eP290	Prospective evaluation of cardiovascular risk in PLWH receiving LA-cabotegravir/rilpivirine Marco Bongiovanni (Switzerland)	09:00 - 09:00
eP291	Relationships between lung health indicators and depressive symptoms, anxiety, resilience, and social support among women with HIV Ken M. Kunisaki (United States)	09:00 - 09:00
eP292	Research on the Diagnostic Value in Cerebrospinal Fluid and Blood Biomarkers of HIV-Associated Neurocognitive Disorders Jiaqi Wei (China)	09:00 - 09:00
eP293	Same Patients, Different Risks: A Head-to-Head of ESC and EACS CVD Guidelines in PLWH Katia Falasca (Italy)	09:00 - 09:00
eP294	Semaglutide Improves Markers of Cardiovascular Risk in People With HIV: The SLIM LIVER Study Jordan Lake (United States)	09:00 - 09:00
eP295	Serum Uric Acid Dynamics in Chinese HIV Patients: A 20-Year Cohort Study Xin Huang (China)	09:00 - 09:00
eP296	Severe Acute Chemsex Intoxications in People Living With HIV: Clinical Insights from a Tertiary-Care ID-ICU Ana Sofia Santos (Portugal)	09:00 - 09:00
eP297	Statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia Rachel Burdon (Australia)	09:00 - 09:00
eP298	Study on the impact and mechanisms of R-CHOP-Based immunochemotherapy on immune status in ARL people	09:00 - 09:00

	Biao Zhu (China)	
eP299	The FIB-4 is a marker of macrophage activation independently from hepatic disease in people living with HIV on stable and successful treatment Matteo Vassallo (France)	09:00 - 09:00
eP300	Understanding hospitalization among people living with HIV (PLWH) in the combination antiretroviral therapy (cART) era: a single-centre retrospective study Antonella Gallicchio (Italy)	09:00 - 09:00
eP301	Use of statins mitigates the impact of smoking on frailty trajectories in people with HIV: a longitudinal cohort study Jovana Milic (Italy)	09:00 - 09:00
eP302	Weight gain and metabolic complications in a large prospective cohort of overweight and obese people with HIV Lucia Taramasso (Italy)	09:00 - 09:00
eP303	Women living with HIV in Australia: Development of a clinical monitoring tool to address gender-specific care gaps and standardize care Rachel Burdon (Australia)	09:00 - 09:00
eP304	A Multidisciplinary Approach to Enhance Quality of Life in Older People Living with HIV: A Comparative Study Fatma Nisa Ballı Turhan (Turkey)	09:00 - 09:00
eP305	Addressing patient-reported outcome measures (PROMs) in routine care does not improve patient's perspective on the receipt of patient-centered care and self-management behavior Roos D Klungers (The Netherlands)	09:00 - 09:00
eP306	Ageing with HIV in France: When PLHIV Needs and Clinical Practice Diverge Daniela Rojas Castro (France)	09:00 - 09:00
eP308	Disability and Physical Activity among Adults Living with HIV in the United Kingdom, Ireland, United States and Canada: A Structural Equation Model Using the Episodic Disability Questionnaire Kelly O'Brien (Canada)	09:00 - 09:00
eP309	Effectiveness of Aerobic Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol Kelly O'Brien (Canada)	09:00 - 09:00
eP310	Effectiveness of Progressive Resistive Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol Kelly O'Brien (Canada)	09:00 - 09:00
eP311	Factors Influencing the Quality of Life Among Men Who Have Sex with Men Living with HIV at an STD Center in Northern Taiwan HsinHao Lai (Taiwan)	09:00 - 09:00
eP312	Integrating HIV and Mental Health Care in Prison: A Complex but Achievable Goal Frederico Duarte (Portugal)	09:00 - 09:00
eP313	Internalized HIV Stigma and Its Influence on Reproductive Intentions of Women Living with HIV in Kazakhstan Batyrbek Assembekov (Kazakhstan)	09:00 - 09:00
eP314	Internalized Stigma and Its Impact on Mental Health and Quality of	09:00 - 09:00

	Life among People Living with HIV in Mauritius Monica Pudaruth (Mauritius)	
eP315	Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects Federica Alessi (Italy)	09:00 - 09:00
eP316	Neurocognitive impairment is associated with functional performance deficits and compromised adherence during follow up in people living with HIV Jose Luis Casado Osorio (Spain)	09:00 - 09:00
eP317	Oral Lesions in People Living with HIV (LINING HIV) Emmanouil Angelos Rigopoulos (Greece)	09:00 - 09:00
eP318	Outcomes of a mental health screening in a cohort of people with HIV Peacchaima Purusothman (Malaysia)	09:00 - 09:00
eP319	Poor Sleep and MASLD are Common in People with HIV and Contribute to Poor Health-Related Quality of Life Ana N Hyatt (United States)	09:00 - 09:00
eP320	Sexual satisfaction in men with HIV aged ≤ 50 years explored with standardized validated questionnaires: prevalence and patterns of various sexual dysfunction, and association with psychosocial factors Nicola Squillace (Italy)	09:00 - 09:00
eP321	Social support and mental health in People Living with HIV: A cross-sectional analysis from a Greek cohort Andronikos Spyrou (Greece)	09:00 - 09:00
eP322	KS evolution in HIV aviremic PLWH: a prospective cohort of the French CancerVIH Network Alain Makinson (France)	09:00 - 09:00
eP323	Prevalence of high-risk human papillomavirus and anal precancerous lesions among men who have sex with men living with HIV in Hong Kong T S Kwong (Hong Kong)	09:00 - 09:00
eP324	Real-World Clinical Insights into Underrecognized Differences in Prostate Cancer Among People Living with HIV Kyoko Yoshida (Japan)	09:00 - 09:00
eP326	Update on German-Austrian Guideline on Screening for Anal Dysplasia and Anal Carcinoma in People Living with HIV David Chromy (Austria)	09:00 - 09:00
	B4. Clinical Science - Pregnancy, children and adolescents	09:00 - 09:00
eP327	Unintended pregnancy among adolescents living with HIV in Africa: a systematic review Mackline Hope (Uganda)	09:00 - 09:00
eP328	HIV diagnosis in pregnancy accounts for 18% of all diagnoses and may reduce advanced stage HIV diagnosis in women over 30 years in the Netherlands Colette Smit (The Netherlands)	09:00 - 09:00
eP329	Life expectancy of premature babies born to HIV-positive mothers Fatima zohra Bensadoun (Algeria)	09:00 - 09:00
eP330	cART use in pregnancy: a real-life experience in Italy Elena Zaninetta (Italy)	09:00 - 09:00

eP331	MISSED OPPORTUNITY: HIV-1 TRANSMISSION CHAIN ACROSS THREE GENERATIONS Ulrike Elisabeth Haars (Germany)	09:00 - 09:00
eP332	Pregnancy monitoring in HIV-serodifferent couples: Support and medical monitoring Fatima zohra Bensadoun (Algeria)	09:00 - 09:00
	C1. Epidemiology/ public health / models of care	09:00 - 09:00
eP333	A Multidisciplinary Offer to Support Emerging Practices: Feedback from the Lounge in Toulouse Dedicated to People Engaging in Chemsex Ali Fendri (France)	09:00 - 09:00
eP334	Acceptability, feasibility, and systemic challenges of community-based antiretroviral therapy delivery model in Cambodia: A qualitative evaluation using the Framework Method Ziya Tian (Singapore)	09:00 - 09:00
eP335	Adaptation and preliminary outcomes of the Community Health Worker Optimization of Antihypertensive Care in HIV (COACH) program: an intervention to address hypertension among people with HIV (PWH) in Tanzania Preeti Manavalan (United States)	09:00 - 09:00
eP336	AI-ntiretroviral preferences Rachel Burdon (Australia)	09:00 - 09:00
eP337	ANALYSIS OF THE CLINICAL COMPLEXITY OF PEOPLE LIVING WITH HIV BASED ON THE GESIDA STRATIFICATION SYSTEM Carolina Olmos Mata (Spain)	09:00 - 09:00
eP338	ARE WE STILL TOO LATE? MISSED OPPORTUNITIES IN THE DETECTION OF HIV Sara Gómez García (Spain)	09:00 - 09:00
eP339	Closing the HIV Testing Gap: Readiness of Pharmacy staff Providing Other Prevention Screenings Natalie Crawford (United States)	09:00 - 09:00
eP340	Costs Associated With People With HIV in France Alexandre Vimont (France)	09:00 - 09:00
eP341	Decentralization of Care? A Comparison of Primary Care Services and Specialized Services in the Care of People Living with HIV in a State in Southern Brazil Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00
eP342	Demographic and Risk Profile Analysis of Users Accessing PrEP Through a Paid Digital Service in the Netherlands: Exploring PrEP Uptake Patterns Beyond Traditional Settings John White (United Kingdom)	09:00 - 09:00
eP343	Enhancing HIV Self-Testing Uptake through Syringe Vending Machines: A Case Study in Tbilisi, Georgia Irma Kirtadze (Georgia)	09:00 - 09:00
eP344	EXPERIENCE OF STRUCTURING A TRANSGENDER-SPECIFIC HIV OUTPATIENT CLINIC AT INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS: AN INTEGRATED CARE PATHWAY MODEL Pisci Bruja Garcia de Oliveira (Brazil)	09:00 - 09:00
eP345	Exploring barriers to pre-exposure prophylaxis among HIV people initiating antiretroviral therapy in Portugal: the POSITIVE CARE study	09:00 - 09:00

	Laura Paixão (Portugal)	
eP346	Exploring the Awareness, Attitudes, and Preferences of People Living with HIV Toward Long-Acting Injectable Treatments Berna Karaismailoğlu (Turkey)	09:00 - 09:00
eP347	General and Family Doctors' perspectives regarding their knowledge, preparedness level and challenges in preventing the Human Immunodeficiency Virus transmission José Ganicho (Portugal)	09:00 - 09:00
eP348	Health care perspectives of People Living with HIV in Central and Eastern Europe (CEE): Results from a Multi-Country Survey Konstantinos Protopapas (Greece)	09:00 - 09:00
eP349	HIV PrEP Need, Availability, and Potential Pharmacy Integration: A Rural-Urban Analysis in the Southern US Siena Senn (United States)	09:00 - 09:00
eP350	HIV viewpoints: survey on the treatment experiences of people living with HIV in Europe Megan Dunbar (United States)	09:00 - 09:00
eP351	Impact of COVID-19 Pandemic on Treatment Outcomes among People Living with HIV in Thailand: A Nested Case-control Study Arnon Techapongsatorn (Thailand)	09:00 - 09:00
eP352	Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified and differentiated PrEP delivery Nicoletta Frattini (Italy)	09:00 - 09:00
eP353	Inpatient burden and diagnosis-specific trends in a dedicated HIV department (2011-2024): a thirteen-year review Andronikos Spyrou (Greece)	09:00 - 09:00
eP355	Linkage to Care and ART initiation: A Retrospective Analysis to guide implementation of rapid ART initiation in outpatient setting Bonnie Chun Kwan Wong (Hong Kong)	09:00 - 09:00
eP356	Mental Well-being and the Work Environment among Healthcare Workers Taking Care of PLWH - Data from the Euroguidelines in Central and Eastern Europe Network Group Agata Skrzat-Klapaczyńska (Poland)	09:00 - 09:00
eP357	Navigating PrEP prescription: an exploratory study on barriers and facilitators among healthcare providers in North Louisiana Camila Castro (Brazil)	09:00 - 09:00
eP358	Outcomes of rapid anti-retroviral therapy (ART) initiation in London, UK Frances Lander (United Kingdom)	09:00 - 09:00
eP359	Prevalence of HIV Indicator Conditions in People with Late Diagnosis of HIV, 25 years on: Are we still missing opportunities for earlier care? Ella Spear (Australia)	09:00 - 09:00
eP360	Provider willingness to discuss and prescribe pre-exposure prophylaxis (PrEP) with women at risk of HIV in Kazakhstan Tara McCrimmon (United States)	09:00 - 09:00
eP361	Quality improvement project aimed at reducing costs of unnecessary investigations in HIV outpatient clinics Aarzo Bhatia (United Kingdom)	09:00 - 09:00
eP362	Reasons for ART interruption related to the war in Ukraine	09:00 - 09:00

	Kseniia Voronova (Ukraine)	
eP363	Reorganizing a HIV clinic in northern Italy for the implementation of Long-Acting Cabotegravir/Rilpivirine for HIV Treatment with limited resources Layla Pagnucco (Italy)	09:00 - 09:00
eP364	Response patterns to a patient-reported outcomes assessment (MyPRO) among racialized women living with and without HIV in a community health clinic in Toronto, Canada Maggie Czarnogorski (United States)	09:00 - 09:00
eP365	Retention of clients diagnosed through Secondary HIV self-testing: A longitudinal analysis over 12 months in Johannesburg, South Africa Mabjala Rosemary Letsoalo (South Africa)	09:00 - 09:00
eP366	Risk factors for sexually transmitted infections in men attending clinics in Jerusalem compared with Tel Aviv Karen Olshtain Pops (Israel)	09:00 - 09:00
eP367	Serum cryptococcal antigen titer as predictor of disseminated Cryptococcosis in people living with HIV Victoria Pinto (Argentina)	09:00 - 09:00
eP368	Significant discrepancies Between Clinical Practice and Medical Guidelines for HPV management in HIV - data from ECEE Network Group Konstantinos Protopapas (Greece)	09:00 - 09:00
eP369	Stigma in the Healthcare Environment: Invisible Barriers Azucena Bautista Hernández (Spain)	09:00 - 09:00
eP370	Telehealth as a tool for expanding PrEP in Argentina Javier José Ricart (Argentina)	09:00 - 09:00
eP371	Tunisian women living with HIV: assessing characteristics and vulnerabilities Rajah Rezgui (Tunisia)	09:00 - 09:00
eP372	Clinical characteristics and treatment patterns among people living with HIV by ART use in the US, 2021-2024 Arlene Nugent (United States)	09:00 - 09:00
eP373	Evaluation of Compliance with EACS Guidelines: Analysis of Error Rates at Baseline, 3, 6, and 12 Months Ece Demirkirkan (Turkey)	09:00 - 09:00
eP374	Factors associated with advanced HIV presentation among individuals referred for inpatient rehabilitation: A continuum of care perspective Simon Rackstraw (United Kingdom)	09:00 - 09:00
eP375	HIV COINFECTION AMONG INDIVIDUALS BELONGING TO KEY GROUPS IN UKRAINE Olena Hridasova (Ukraine)	09:00 - 09:00
eP376	Outcomes of rapid initiation of antiretroviral therapy among people living with HIV: real-world experience from a tertiary care hospital in Thailand Niti Aueaphongkarun (Thailand)	09:00 - 09:00
eP377	"Bridging the Last Mile: A Low-Cost, Gender-Responsive Model Integrating Real-Time Viral Load Dashboards and Task-Shifting in Rural Nigeria" Okeoghene Akusu (Nigeria)	09:00 - 09:00

eP378	Addressing health inequities in HIV testing: Effectiveness of activation of community-based networks and use of app technology to reach and support diverse, marginalized and underserved populations to access HIV self-testing in Canada Sean B. Rourke (Canada)	09:00 - 09:00
eP379	Breaking STI Chains with <i>Con-Tacto</i>: Acceptability of an Anonymous Partner Notification App Among PrEP Users Felix Straga Napolitano (Spain)	09:00 - 09:00
eP380	Challenges in implementing a strategy for the triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B: the experience of the TRI-MOM project in The Gambia SEYDOU DRABO (France)	09:00 - 09:00
eP381	Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis Toshibumi Taniguchi (Japan)	09:00 - 09:00
eP382	How Rapid is the Recommended Timing of Antiretroviral Therapy Initiation? Preliminary Findings from a Scoping Review of HIV Clinical Guidelines Moustafa Laymouna (Canada)	09:00 - 09:00
eP383	If we build it, will they come? Pharmacists' perspectives on recruiting people to a pharmacy-based sexually transmitted and bloodborne infection (STBBI) testing service Deborah Kelly (Canada)	09:00 - 09:00
eP384	Introducing the CROSS framework for developing and implementing inclusive and scalable research: Insights from the co-production and delivery of a cross-country HIV survey with migrant women within EACS/WAVE's SERAY project (Strengthening health Equity Research through Active involvement of Non-Governmental Organisations and migrant women) Melvina Woode-Owusu (United Kingdom)	09:00 - 09:00
eP385	Negative Beliefs About Methadone and Barriers to Opioid Agonist Therapy in Kazakhstan: Findings from a Multi-City RDS Study Assel Terlikbayeva (Kazakhstan)	09:00 - 09:00
eP386	Piloting the digital distribution and implementation of the Positive Outcomes PROM in HIV Outpatients Rebekah Morris (United Kingdom)	09:00 - 09:00
eP387	Psychosocial Needs in Migrants with HIV: Implications for Care Joanna Cano-Smith (Spain)	09:00 - 09:00
eP388	The impact of Shared Decision-Making on Long-Acting Injectable Antiretroviral Therapy in People Living with HIV in Taiwan LIAN LIN (Taiwan)	09:00 - 09:00
eP389	Using Mixed-Methods Operations Research to Evaluate Community-Led Monitoring for Improved HIV Service Delivery in Nigeria Joy Egwu (Nigeria)	09:00 - 09:00
eP390	Willingness and Ability of People Living with HIV to use Patient-Reported Outcome Measures in Routine HIV Care: Preliminary Results from the PRO-CARE Study Olivia Borchmann (Denmark)	09:00 - 09:00
eP391	Causes of Death in People Living with Human Immunodeficiency Virus in Türkiye: A Multicentre Retrospective Study Adalet Altunsoy (Turkey)	09:00 - 09:00
eP392	Challenges in Managing People Living with HIV in Critical Care:	09:00 - 09:00

	Experience from Mexico Paulina Carreño Pérez (Mexico)	
eP393	Unstable housing and its associations with mental health and alcohol use among persons living with HIV (PLWH): Findings from the Florida Cohort Wave 4 survey Yan Wang (United States)	09:00 - 09:00
eP394	Demographics of under-housed individuals living with HIV in British Columbia, Canada Christina Wiesmann (Canada)	09:00 - 09:00
eP395	Epidemiological Profile of Pregnant Women Living with HIV in Brazil: A Cross-Sectional Analysis of National Surveillance Data Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00
eP396	Epidemiology of Human Immunodeficiency Virus HIV in Tunisia in 2024 Arwa Neffati (Tunisia)	09:00 - 09:00
eP397	Estimating HIV incidence and associated risk factors using longitudinal community-based testing data across the WHO European Region: Insights from the COBATEST Network Laura Fernández-López (Spain)	09:00 - 09:00
eP398	HIV seropositivity in key or vulnerable population at higher risk: results of rapid testing program in the Russian Federation during 2020-2024 Elena Sklyarskaya (Russian Federation)	09:00 - 09:00
eP399	Impact of the COVID-19 Pandemic on HIV Case Detection in Georgia: An Interrupted Time Series Analysis (2018-2024) Otar Chokoshvili (Georgia)	09:00 - 09:00
eP400	Incidence of HIV and STI After Initiating Pre-Exposure Prophylaxis, Among Men who have Sex with Men in Georgia: Findings from Routine Program Surveillance, 2020-2024 Otar Chokoshvili (Georgia)	09:00 - 09:00
eP401	Knowledge, Attitude and Practice on HIV/AIDS among University Students in Kilimanjaro Region aged 18 to 45 years. A Cross Sectional Study Simon Ernest (Tanzania)	09:00 - 09:00
eP402	Migration and HIV in Latin America: a multicenter regional descriptive study María Marta Greco (Argentina)	09:00 - 09:00
eP403	Migration-Linked Transmission of HIV-1 Subtype A6 in Europe: Evidence from Multinational Molecular Cluster Analysis Karol Serwin (Poland)	09:00 - 09:00
eP404	Missed Lessons, Missed Protections: Strengthening Adolescent STI and HIV Awareness Through Targeted Educational Interventions Gunda Waldmann (Germany)	09:00 - 09:00
eP406	Phylogenetic analysis and transmission networks highlight the role of older adults in the transmission of HIV-1 in northern Zhejiang, China xiaohong Pan (China)	09:00 - 09:00
eP407	Pre-exposure prophylaxis (PrEP) and the reduction in new cases of HIV acquisition in men in the state of Sao Paulo, Brazil Mariza Vono Tancredi (Brazil)	09:00 - 09:00
eP408	Seroprevalence of HIV, HBV and HCV Among People Who Use	09:00 - 09:00

	Drugs in Turkey Ali Asan (Turkey)	
eP409	Seroprevalence of Toxoplasma gondii in Individuals Living with HIV/AIDS: An Epidemiological Assessment and Clinical Significance Merve Kılıç Tekin (Turkey)	09:00 - 09:00
eP410	Sex-Based Disparities in Hospitalizations due to Advance Disease among People Living with HIV in a Tertiary Center from 2003-2023 in Mexico City Santiago Agraz Orozco (Mexico)	09:00 - 09:00
eP411	Structural Barriers and HIV Testing Uptake Among Female Sex Workers in Albania: Findings from Integrated Bio-Behavioral Surveillance Elona Gjebrea Hoxha (Albania)	09:00 - 09:00
eP412	The Relationship Between Development Indicators and HIV Epidemiology: A Global Perspective on Social Determinants Özge Eren Korkmaz (Turkey)	09:00 - 09:00
eP413	Trends in HIV awareness, screening practices and attitudes in Tunisia: Insights from MICS Data (2012-2023) Mariem Noura (Tunisia)	09:00 - 09:00
	C2. HIV prevention	09:00 - 09:00
eP415	Clinic vs. Self HIV Testing in Southern Africa: A Systematic Review on Progress Towards UNAIDS Targets David Flynn (United Kingdom)	09:00 - 09:00
eP416	Effectiveness of the HIV Testing Month campaign in promoting testing in the general public in Hong Kong Tsz Ho Kwan (Hong Kong)	09:00 - 09:00
eP418	Estimating the health impact and cost-effectiveness of emergency department opt-out testing for blood-borne viruses in Germany Jürgen K Rockstroh (Germany)	09:00 - 09:00
eP419	Expanding HIV Screening Beyond Hospital Walls in Milan: 18 years of the "EasyTest" project Angelo Roberto Raccagni (Italy)	09:00 - 09:00
eP421	HIV Screening Practices and Knowledge of Indicator Conditions Among Resident Doctors: A Cross-Sectional Study Mehmet Buğra Özkara (Turkey)	09:00 - 09:00
eP422	Individuals newly diagnosed with HIV in London, UK: characteristics of previous attenders and 'never-attenders' Sheel Patel (United Kingdom)	09:00 - 09:00
eP423	Involvement of key populations in HIV testing through social networks, Odesa, Ukraine Nataliia Kitsenko (Ukraine)	09:00 - 09:00
eP424	Medical-Driven HIV Testing Persists Over Time in Central and Eastern Europe: Evidence from the Go Holistic Go Beyond Project Ivana Gmizic (Serbia)	09:00 - 09:00
eP425	Missed Opportunities for HIV Testing in Newly Diagnosed Patients at a Tertiary Care Hospital: A Retrospective Analysis Bircan Kayaaslan (Turkey)	09:00 - 09:00
eP426	NEW OPPORTUNITIES FOR COVERING THE POPULATION WITH HIV TESTING IN LVIV, UKRAINE Olena Pavlyshyn (Ukraine)	09:00 - 09:00

eP427	Overview on community-based screening in Tunisia in 2024 Arwa Neffati (Tunisia)	09:00 - 09:00
eP428	Use of Regional Mentors to Optimize Maternal Retesting Services for Prevention of Vertical Transmission of HIV: A case of Mwanza, Tabora, and Morogoro in Tanzania Neema Makyao (Tanzania)	09:00 - 09:00
eP429	Wedge-shaped clustered randomized trial to evaluate two tools for identifying individuals at risk for or already infected with HIV: Atenea Study Interim Analysis María Jesús Pérez- Elías (Spain)	09:00 - 09:00
eP430	Female Patients on HIV Post-Exposure Prophylaxis: Clinical outcomes and prevention opportunities Natalia Sánchez-Ocaña Martín (Spain)	09:00 - 09:00
eP431	HIV post-exposure prophylaxis in the integrase inhibitor era: Experience in a low-middle income country Mariana Ariadna Paolini (Argentina)	09:00 - 09:00
eP432	Rapid assessment of access to HIV Post-Exposure Prophylaxis (PEP) in EU/EEA countries Ferenc Bagyinszky (Germany)	09:00 - 09:00
eP433	A Multidisciplinary Approach to Promoting Accessibility and Adherence to Pre-Exposure Prophylaxis (PrEP) in a Portuguese Hospital in Lisbon Bárbara Cardoso (Portugal)	09:00 - 09:00
eP434	Assessing the Interest and Willingness of Nigerian Community Pharmacists to Deliver Pharmacy-Based Pre-Exposure Prophylaxis (PrEP) Services Theodora Chioma Omenoba (Nigeria)	09:00 - 09:00
eP435	Assessment of healthcare access and knowledge of HIV pre-exposure prophylaxis in women sex workers in Lille, Northern France. Emmanuelle Bontemps (France)	09:00 - 09:00
eP436	Automated Data Solutions for PrEP Monitoring and Planning in Ukraine Diana Shevchenko (Ukraine)	09:00 - 09:00
eP437	Awareness and uptake of pre-exposure prophylaxis among pregnant women at risk of HIV in mid-western and central Uganda: a population-based study Bashiri Magada (Uganda)	09:00 - 09:00
eP438	Characteristics of PrEP Users at First Counseling Visit: Persistent Gaps in Reaching High-Risk Populations Drieda Zace (Italy)	09:00 - 09:00
eP439	Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP) Sandro Mattioli (Italy)	09:00 - 09:00
eP440	Comparison of users accessing PrEP in hospital-based or community-based setting: first picture from the PrIDE cohort Valentina Mazzotta (Italy)	09:00 - 09:00
eP441	Engagement of Women of Color in HIV Prevention through PrEP at a Clinic Serving LGBTQ+ Communities Darya Fridman (United States)	09:00 - 09:00
eP442	Evaluation of a multidisciplinary reach-out program, facilitating	09:00 - 09:00

	HIV pre-exposure prophylaxis (PrEP) prescription and retention in care, in a group of trans women (TW) at high risk of HIV infection. Preliminary results from the PrEP à porter study VALENTINA ISERNIA (France)	
eP443	Examining the real-world population-level impact of Scotland's national HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men Claudia Estcourt (United Kingdom)	09:00 - 09:00
eP444	Experience of Implementing PrEP in a Health Insurance in Buenos Aires, Argentina: Lessons Learned and Challenges Iael Altclas (Argentina)	09:00 - 09:00
eP445	Frequency of Enteric Pathogens in Austrian PrEP Users Nikolaus Urban (Austria)	09:00 - 09:00
eP446	HIV infection in PrEP users: incidence, epidemiological, clinical and virological characteristics. A multicenter ambispective Cohort in Spain (SCOPE Study) Juan Ambrosioni (Spain)	09:00 - 09:00
eP447	Impact of COVID-19 lockdown on HIV pre-exposure prophylaxis (PrEP) service delivery in Uganda: Challenges and coping strategies Sylvia Namanda (Uganda)	09:00 - 09:00
eP448	Impact of Pre-Exposure Prophylaxis (PrEP) Introduction on Homosexual HIV Transmission in Kazakhstan: An Interrupted Time Series Analysis Indira Karibayeva (Kazakhstan)	09:00 - 09:00
eP449	Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey Silvia Nozza (Italy)	09:00 - 09:00
eP450	Inequality in the Distribution of PrEP in Brazil: An Analysis of Coverage in Relation to HIV Incidence by Age Group, Sexual Orientation, and Race Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00
eP451	Interest in and intention to use long-acting PrEP among PrEP-naive MSM and MSM currently using PrEP in Thailand Natthakhet Yaemim Deyn (Thailand)	09:00 - 09:00
eP452	Introducing community-based PrEP delivery in Romania Raluca Pătraşcu (Romania)	09:00 - 09:00
eP453	Introduction of pre-exposure prophylaxis (PrEP) in Kazakhstan: its impact on HIV testing and diagnosis rates among people who inject drugs Indira Karibayeva (Kazakhstan)	09:00 - 09:00
eP454	Mental Health, Stigma and Risk Perception Among CAB-LA PrEP Initiators: a cross-sectional study Davide Moschese (Italy)	09:00 - 09:00
eP455	Mind the Gap: transition from HIV PEP with B/F/TAF to oral PrEP in real-world setting Flavia Passini (Italy)	09:00 - 09:00
eP456	Opportunities to Prevent Human Immunodeficiency Virus (HIV) Acquisition: Global Survey Results on Sexual Health Engagement in Newly Diagnosed People Living With HIV From the VOLITION Study Cassidy A Gutner (United States)	09:00 - 09:00

eP457	Pre-Exposure prophylaxis to prevent HIV transmission among migrant men who have sex with men in Georgia Maia Tsintsadze (Georgia)	09:00 - 09:00
eP458	Prevalence and Correlates of Intimate Partner Violence among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) Using PrEP in Pre-War Ukraine Nikolay Lunchenkov (Germany)	09:00 - 09:00
eP459	Real-World Experience with Oral PrEP in Italy: A Descriptive Study from a Single-Center Cohort (2018-2024) Andrea Carbone (Italy)	09:00 - 09:00
eP460	Reasons for HIV-Preexposure Prophylaxis (PrEP) discontinuation and its predictors in people still at risk for HIV acquisition Virginia Barchi (Italy)	09:00 - 09:00
eP461	Sexual health knowledge, interest and acceptability of PrEP in migrant women: the MIMOSA study Maria Mazzitelli (Italy)	09:00 - 09:00
eP462	Social Media Communication for Recruitment and Adherence to Combined HIV/STI Prevention with a Focus on the Trans Population at a Research Center, São Paulo, Brazil Vinicius Francisco da Silva (Brazil)	09:00 - 09:00
eP463	Systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men David Comer (Ireland)	09:00 - 09:00
eP464	Use of whole blood capillary samples to estimate glomerular filtration rate using enzymatic analysis of creatinine among HIV PrEP users Maurice Pelsers (Germany)	09:00 - 09:00
eP465	Would infant lamivudine prophylaxis during breastfeeding be an option to prevent from vertical transmission of HIV ? Laetitia Gay (France)	09:00 - 09:00
eP466	Durable viral load suppression and viral load rebound among people living with HIV in North America and Europe. A systematic review and meta-analysis Mariam Salim Mbwana (Tanzania)	09:00 - 09:00
eP467	HIV Self-Testing by Mail Among Sex Workers: A Virtual Harm Reduction Initiative in Montpellier, France Victor Duperret (France)	09:00 - 09:00
eP468	MEASURING HIV PREVENTION KNOWLEDGE (U=U, PEP, PrEP) AND ATTITUDES IN THE HEALTHCARE SETTING: SERBIAN RESULTS FROM AN ECDC/EACS SURVEY Gordana Dragović (Serbia)	09:00 - 09:00
eP469	Treatment as prevention: the impact of the national care and support program for people living with HIV amid Russia's full-scale military invasion of Ukraine Olha Anatoliivna Klymova (Ukraine)	09:00 - 09:00
	C3. Social Sciences	09:00 - 09:00
eP470	Advancing HIV Cure Research in Latin America and the Caribbean: Perspectives, Priorities, and Advocacy Needs of Civil Society Luciana Kamel (Brazil)	09:00 - 09:00
eP471	Behavioral Change Related to Stigma and Discrimination Among	09:00 - 09:00

	People Living with HIV Monica Pudaruth (Mauritius)	
eP472	Evaluation of health-related quality of life over a six-month period in newly diagnosed people living with HIV Banu Çiçek Aktaş (Turkey)	09:00 - 09:00
eP473	Evolving Influences on HIV Knowledge in Young Filipino Women: Education, Media, and Stigma Sophia Palma (Hungary)	09:00 - 09:00
eP474	Memory rehabilitation for HIV-Associated Neurocognitive Disorders (HAND) : A review of the literature Signe Andersen (France)	09:00 - 09:00
eP475	Multi-dimensional impulsivity in people living with HIV on effective cART Chloe Knox (United Kingdom)	09:00 - 09:00
eP476	Preliminary findings from a new group-based memory rehabilitation program, <i>Coaching Memory</i>, for HIV-Associated Neurocognitive Disorders (HAND) Signe Andersen (France)	09:00 - 09:00
eP477	Reframing HIV: How Personal Growth and Acceptance Could Improve ART Adherence Andrea Norcini-Pala (United States)	09:00 - 09:00
eP478	Time to Suboptimal Treatment Patterns Among People With HIV on Antiretroviral Therapy in the United States Travis Lim (United States)	09:00 - 09:00
eP479	A Telegram Bot as a Digital Tool for Transgender People in Ukraine: Access to HIV Services and Gender-Affirmative Support Vitalii Apanasenko (Ukraine)	09:00 - 09:00
eP480	Bimonthly long acting cabotegravir and rilpivirine in transgender women with HIV: evidence from the Spanish RELATIVITY cohort. Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP481	Integrated biobehavioral survey among transgender and non-binary people in Ukraine, 2024 Sofia Ohorodnik (Ukraine)	09:00 - 09:00
eP482	Effect of SARS-CoV-2 vaccination on HIV viral load in patients under BIC/TAF/FTC therapy: a retrospective observational study Chiara Iaria (Italy)	09:00 - 09:00
eP483	Gamified Education: Utilizing Interactive Play to Enhance HIV/AIDS Awareness and Prevention Olga Feger (Ukraine)	09:00 - 09:00
eP484	Loneliness and HIV in Adults 50+: Voices on Needed Interventions Rosa De Miguel Buckley (Spain)	09:00 - 09:00
eP485	More than just a drink: Identifying and intervening on silent risk profiles for alcohol misuse in People Living With HIV Andronikos Spyrou (Greece)	09:00 - 09:00
eP486	Perspectives on HIV Cure-Related Trials with Analytical Treatment Interruption among People Living with HIV and Healthcare Practitioners Kwanza Price (United States)	09:00 - 09:00
eP487	Reasons for interrupting antiretroviral therapy, results of the study	09:00 - 09:00

	Yaroslava Lopatina (Ukraine)	
eP488	Silent Crisis: Loneliness in Older Adults Living with HIV Joanna Cano-Smith (Spain)	09:00 - 09:00
eP489	Stigma and Quality of Life in People Living with HIV: Psychosocial vulnerability and clinical implications Carolina Olmos Mata (Spain)	09:00 - 09:00
eP490	Cost analysis and diagnostic yield of asymptomatic sexually transmitted infections (STIs) screening in a high-risk cohort of men who have sex with men (MSM) Pierluigi Francesco Salvo (Italy)	09:00 - 09:00
eP491	Feelings, experiences and coping strategies after HIV diagnosis amongst people with recently acquired HIV in Europe Inés Suárez-García (Spain)	09:00 - 09:00
eP492	Leveraging interactive SMS training to equip health workers for inclusive HIV services amid Uganda's anti-gay law implementation Christine Nabukera Rwabyogamu (Uganda)	09:00 - 09:00
eP493	Navigating sexual dysfunction with HIV: experiences of gay, bisexual, and other men who have sex with men in Montreal, Canada Bertrand Lebouché (Canada)	09:00 - 09:00
eP494	Risk reduction strategies for HIV transmission during time among men who have sex with men in Slovenia: Qualitative study Miran Solinc (Slovenia)	09:00 - 09:00
eP495	"Even Me Myself, I Don't See Myself as a Human Being": Migration, Violence, and HIV Exposure Among African Refugee Male Sex Workers in Transit to Italy Marco Barracchia (The Netherlands)	09:00 - 09:00
eP496	Assessing Mental Health in an Immigrant-Dominated HIV Cohort Using PHQ-9: A Pilot Analysis from a Greek HIV Unit Vissaria Sakka (Greece)	09:00 - 09:00
eP497	Characterisation of migrant PLWHIV from sub-Saharan Africa in a hospital in Europe - mixed-methods study in the Lisbon region, Portugal Rita Patrocínio de Jesus (Portugal)	09:00 - 09:00
eP498	Where Health Begins: Mobile Health as a Tool for HIV/STI Access Among LGBTQI+ Migrants in Italy Marco Barracchia (The Netherlands)	09:00 - 09:00
eP499	Attitudes towards PrEP among women engaged in sex work who use drugs (WESW-UD) in Kazakhstan Tara McCrimmon (United States)	09:00 - 09:00
eP501	Did the AEGIDA Intervention Reduce Sexual Behaviors Associated with HIV Acquisition among Women who Exchange Sex and/or Use Substances in Kazakhstan? Victoria Frye (United States)	09:00 - 09:00
eP502	Health issues in sex workers attending a sexual health clinic in Paris: an observational cohort Sarah Gaston-Dreyfus (France)	09:00 - 09:00
eP503	Internalized Stigma and Mental Health Symptoms among females who engage in sex work and use drugs in Kazakhstan: Baseline insights from the AEGIDA Study Assel Terlikbayeva (Kazakhstan)	09:00 - 09:00

eP504	Intersectional identities and barriers Trajche Janushev (Hungary)	09:00 - 09:00
eP505	Retention Cascade and Predictors in a Sexual Health Program for Sex Workers: Expanded Access Through NGO Collaboration Diana Corona-Mata (Spain)	09:00 - 09:00
eP506	Associations Between Marijuana Use Patterns and HIV Care Continuum Outcomes Among Adults with HIV in Florida Robert Cook (United States)	09:00 - 09:00
eP507	Chemsex Trajectories among GBMSM in Almaty, Kazakhstan: A Reflexive Thematic Analysis Using a Life Course Framework Nikolay Lunchenkov (Germany)	09:00 - 09:00
eP508	Co-designing community-led, comprehensive chemsex harm reduction services for young men who have sex with men in Thailand: sexual health-focused, legal/rights-focused, and on-the-spot models Sudarat Thongsuksangcharoen (Thailand)	09:00 - 09:00
eP509	Describing substance use related to sex (chemsex) among individuals newly diagnosed with HIV at a sexual health clinic in Spain Inés Armenteros-Yeguas (Spain)	09:00 - 09:00
eP510	Peer-to-peer needle and syringe programmes (P2PNSP) as a way of engaging PWID in HIV prevention: 7 case studies Alexei Lakhov (Germany)	09:00 - 09:00
eP511	The Silent Epidemic: Chemsex Practices and Their Implications in Turkiye Gökhan Vatansever (Turkey)	09:00 - 09:00
eP512	Trends in HIV prevalence among key populations between 2009 and 2021 Arwa Neffati (Tunisia)	09:00 - 09:00
eP513	AEGIDA: A Behavioral HIV Intervention Associated with Reduced Partner Violence Among Women Who Exchange Sex and Use Substances (WESUS) in Kazakhstan Sholpan Primbetova (Kazakhstan)	09:00 - 09:00
eP514	Barriers to HIV Services for LGBT+ People in Armenia: Legal Gaps, Stigma, and Human Rights Concerns Vaghinak Ter-Hovhannisyán (Armenia)	09:00 - 09:00
eP515	Community and provider-driven strategies to reduce HIV-related stigma in Kazakhstan: opportunities for change Meruyert Darisheva (Kazakhstan)	09:00 - 09:00
eP518	HIV and STIs Prevention in Women in Italy: the importance of the educational setting in WomanIST project Dario Bernacchia (Italy)	09:00 - 09:00
eP519	HIV-RELATED STIGMA AND DISCRIMINATION IN ARGENTINA'S POPULATION: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY José A. E. Barletta (Argentina)	09:00 - 09:00
eP520	Medical Mistrust as a Barrier to Healthcare Access Among Women Vulnerable to HIV Meruyert Darisheva (Kazakhstan)	09:00 - 09:00
eP521	Overview on the epidemiology of HIV/AIDS among key populations in Tunisia, 2024	09:00 - 09:00

	Arwa Neffati (Tunisia)	
eP522	Prison: An Essential Piece in the 'Towards Zero' Puzzle Pankaj Sethi (United Kingdom)	09:00 - 09:00
eP523	Reaching neglected Vulnerable Populations: Addressing the HIV Knowledge Gap in UK prisons Sophie Strachan (United Kingdom)	09:00 - 09:00
eP524	Religiosity and Perceived Stress Among Filipino People Living with HIV: Evidence from a Community-Led Treatment Hub in Metro Manila, Philippines Emmanuel S. Baja (Philippines)	09:00 - 09:00
eP525	Understanding HIV and Key Population Stigma in Kazakhstan's Healthcare Workforce: A Cross-Sectional Analysis Gaukhar Mergenova (Kazakhstan)	09:00 - 09:00
eP526	HIV/AIDS IN LVIV (UKRAINE) IN WAR CONDITIONS: EPIDEMIOLOGICAL CHANGES Olena Mysano (Ukraine)	09:00 - 09:00
eP527	Impact of the War on HIV Diagnosis Timeliness: CD4 Level Dynamics Among Newly Registered PLHIV in Ukraine Larysa Hetman (Ukraine)	09:00 - 09:00
eP528	Resilience of Harm Reduction and HIV Prevention Services for People Who Inject Drugs in Ukraine Amid War: Insights from 2021-2023 Liudmyla Legkostup (Ukraine)	09:00 - 09:00
	Clinical Cases	09:00 - 09:00
eP.C001	Possible CNS compartmentalization and lenacapavir resistance in multidrug-resistant HIV Annalisa Marinosci (Switzerland)	09:00 - 09:00
eP.C002	Virological failure with NNRTI resistance on CAB+RPV-LA in a man with subtherapeutic cabotegravir levels Nian Li (United Kingdom)	09:00 - 09:00
eP.C003	Bictegravir in aging adults living with HIV: sustained virologic control and age-appropriate safety profile Marcello Trizzino (Italy)	09:00 - 09:00
eP.C004	Central nervous system lesions in late-presenting person living with HIV - opportunistic infection or a brain tumour? Filip Glavac (Croatia)	09:00 - 09:00
eP.C005	Case report: late diagnosis of HIV at clinical stage 4 with pulmonary and CNS tuberculosis Oleksandra Bezrodna (Ukraine)	09:00 - 09:00
eP.C006	Evolving genital lesions of unusual etiology in a man who have sex with man: case report Carlo Bieńkowski (Poland)	09:00 - 09:00
eP.C007	CMV-related cholangiopathy as part of IRIS in an HIV-infected patient with invasive pulmonary aspergillosis Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP.C008	Bacillary angiomatosis in a HIV patient with high CD4 count: an unexpected manifestation of IRIS? Hayat Kumbasar Karaosmanoğlu (Turkey)	09:00 - 09:00
eP.C009	Disseminated Whipple's disease and Kaposi's Sarcoma with IRIS-	09:00 - 09:00

	PML in an individual with advanced HIV Alexy Inciarte Portillo (Spain)	
eP.C010	Disseminated MAC, Leishmaniasis, and CMV in a patient with advanced HIV: a complex case of IRIS Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP.C011	A case of AIDS-associated progressive multifocal leukoencephalopathy with significant improvement in higher brain function following glucocorticoid therapy Motoki Kon (Japan)	09:00 - 09:00
eP.C012	Fatal case of KSHV-associated diseases with airway involvement: Kaposi Sarcoma, Multicentric Castleman Disease, and Diffuse Large B-Cell Lymphoma in a Person living with HIV Vitor José da Silva Classmann (Brazil)	09:00 - 09:00
eP.C013	When the fever won't break: a case of disseminated MAC in advanced HIV ilkay akbulut (Turkey)	09:00 - 09:00
eP.C014	Visceral Leishmaniasis and HIV coinfection: unusual clinical presentation Lorenzo Albertini (Italy)	09:00 - 09:00
eP.C015	A rare and fatal case of cerebral and renal toxoplasmosis in a non-adherent person living with advanced HIV Büşra Akmaz (Turkey)	09:00 - 09:00
eP.C016	Encephalitis caused by ganciclovir-resistant cytomegalovirus in a late-presenting person living with HIV, diffuse large B-cell lymphoma, and multiple opportunistic infections Marija Santini (Croatia)	09:00 - 09:00
eP.C017	Disseminated Mycobacterium Avium Complex (dMAC) and Ophthalmoplegia - a diagnostic challenge Niroshan Dayalan (United Kingdom)	09:00 - 09:00
eP.C018	The first case of lung abscess and bacteremia caused by Rhodococcus hoagii in a patient with advanced HIV infection in Croatia - a therapeutic challenge Nikola Kudoić (Croatia)	09:00 - 09:00
eP.C019	First reported case of <i>Trichophyton mentagrophytes</i> genotype VII infection in a Portuguese HIV-positive patient Fábio Reis (Portugal)	09:00 - 09:00
eP.C020	Maribavir salvage therapy for ganciclovir-resistant cytomegalovirus in two women with HIV-related lymphoma Guillaume THIZY (France)	09:00 - 09:00
eP.C021	Paradoxical Immune Reconstitution Inflammatory Syndrome associated with <i>Pneumocystis jirovecii</i> pneumonia in a person living with HIV: a case report Dara Mbanze (Portugal)	09:00 - 09:00
eP.C022	Treatment of refractory Giardiasis with quinacrine in a young refugee with HIV and HCV coinfection	09:00 - 09:00
eP.C023	HIV-associated chronic inflammatory demyelinating polyneuropathy successfully managed with immunoadsorption Yuanmei Che (China)	09:00 - 09:00
eP.C024	Polymorphic Kaposi Sarcoma in the shadows of isolation and migration Andronikos Spyrou (Greece)	09:00 - 09:00

eP.C025	<i>Mycobacterium avium</i> complex infection following immune reconstitution inflammatory syndrome: a diagnostic journey Daniela Rodrigues Nogueira (Portugal)	09:00 - 09:00
eP.C026	Oral ulcerations associated with Epstein-Barr virus in a severely immunocompromised person living with HIV-1 Márcia Daniela Silva (Portugal)	09:00 - 09:00
eP.C027	Genital and oral ulcerative vasculitis in a recently diagnosed PWH with negative microbiological workup Alberto Foncillas (Spain)	09:00 - 09:00
eP.C028	An atypical presentation of psychosis in progressive multifocal leukoencephalopathy Natasha Somani (United Kingdom)	09:00 - 09:00
eP.C029	Fatal overlapping CMV encephalitis, adrenal insufficiency, and IRIS in an individual with advanced HIV and disseminated MAI Alexy Inciarte Portillo (Spain)	09:00 - 09:00
eP.C030	Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution Maria Felipe Medeiros (Brazil)	09:00 - 09:00
eP.C031	Emergence of maribavir resistance in an AIDS patient with refractory cytomegalovirus viremia and retinitis Vissaria Sakka (Greece)	09:00 - 09:00
eP.C032	Severe disseminated cryptococcosis, with asymptomatic central nervous system involvement, in a very late presenter Gabriela-Andreea Stoica (Romania)	09:00 - 09:00
eP.C033	A case of an AIDS related multifocal cryptococcus infection Sergei Rakovich (Belarus)	09:00 - 09:00
eP.C034	Unmasking IRIS due to <i>Toxoplasma gondii</i> in a new HIV-positive individual with CD4 \geq 200 cells/mm³ and disseminated tuberculosis Francisco Vale (Portugal)	09:00 - 09:00
eP.C035	Cryptococcal meningitis in a 34-year-old man with advanced HIV and left insular astrocytoma Alexy Inciarte Portillo (Spain)	09:00 - 09:00
eP.C036	Nocardia abscessus diagnosis in a cis gender woman living with HIV Javier José Ricart (Argentina)	09:00 - 09:00
eP.C037	Clinical case of advanced HIV with multiple opportunistic diseases: pneumocystis pneumonia, CMV chorioretinitis, and Kaposi's sarcoma Olena Vinnytska (Ukraine)	09:00 - 09:00
eP.C038	Immune reconstitution inflammatory syndrome with atypical presentation of varicella zoster virus encephalitis Javier José Ricart (Argentina)	09:00 - 09:00
eP.C039	Diagnostic and therapeutic challenges in a case of cerebral mass lesions in a person living with HIV Nathalie De Castro (France)	09:00 - 09:00
eP.C040	Spondilodiscitis caused by <i>M. avium</i> complex in a man living with HIV and poor immunological - recovery after HAART Laura Comi (Italy)	09:00 - 09:00
eP.C041	Multiple concurrent opportunistic infections in newly diagnosed HIV-positive patient	09:00 - 09:00

	Graciana Lucia CARDENAS (Argentina)	
eP.C042	Disseminated <i>Talaromyces marneffe</i> infection presenting as pulmonary cavitary nodules: a case report Jun ZOU (China)	09:00 - 09:00
eP.C043	A case of disseminated <i>Trichosporon asahii</i> infection in a patient with advanced human immunodeficiency virus disease and Kaposi sarcoma Theodoros Michailidis (Greece)	09:00 - 09:00
eP.C044	Coexistence of Multicentric Castleman disease and visceral Kaposi Sarcoma: a case-report Su Jung Choi (Mexico)	09:00 - 09:00
eP.C045	Multicentric Castleman disease as a cause of fever of unknown origin: a case report Su Jung Choi (Mexico)	09:00 - 09:00
eP.C046	Overcoming barriers in care: managing HIV in people with disabilities Thyago César da Silva Pires (Brazil)	09:00 - 09:00
eP.C047	Advanced coronary artery disease in a low-risk HIV patient - a case for early statin intervention Aishriah Kalearasu (United Kingdom)	09:00 - 09:00
eP.C048	Diffuse large B-cell lymphoma in a person living with HIV and a history of leprosy: a diagnostic challenge Dilek Yildiz Sevgi (Turkey)	09:00 - 09:00
eP.C049	Use of PCSK9 inhibitor evolocumab in PLWH with persistent hyperlipidemia despite statin therapy: two case reports Layla Pagnucco (Italy)	09:00 - 09:00
eP.C050	Complete remission of a large B-cell Lymphoma in a person living with HIV: a case report with a 16 year follow-up Kateryna Lytvyn (Ukraine)	09:00 - 09:00
eP.C051	Interaction between GLP-1 receptor agonists and cART in PLWH and obesity: a case report Raffaele Ferri (Italy)	09:00 - 09:00
	Late-breaking Abstracts	09:00 - 09:00
eP.LB001	GPR56 marks exhausted, clonally expanded and cytotoxic CD4+ T cell subset in people living with HIV-1 Tom Kraus (Germany)	09:00 - 09:00
eP.LB002	Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland Agnieszka Lembas (Poland)	09:00 - 09:00
eP.LB003	Long-acting cabotegravir plus rilpivirine in viremic PWH: virological outcomes from the French Dat'AIDS cohort Colin Deschanvres (France)	09:00 - 09:00
eP.LB004	Antiviral efficacy of doravirine-based regimens in patients with NNRTI resistance in Europe: a retrospective observational study Pierre Sellier (France)	09:00 - 09:00
eP.LB005	Real-World 5-Year Virological Outcomes of People Living with HIV Initiated on Efavirenz or Dolutegravir or Switched to Dolutegravir Containing Regimens in Botswana, 2012-2025 Ava Avalos (Botswana)	09:00 - 09:00

eP.LB006	Drug-Drug Interaction (DDI) Liability of Bictegravir/Lenacapavir (BIC/LEN) Compared With Representative Complex Antiretroviral Therapy (ART) Regimens in the Phase 3 Portion of ARTISTRY-1 Priyanka Arora (United States)	09:00 - 09:00
eP.LB007	High Effectiveness and Rare Virologic Failure in Treatment-Experienced Individuals on Long-Acting Cabotegravir + Rilpivirine Therapy Across Europe: Insights from the EuroSIDA Study Wendy Bannister (Denmark)	09:00 - 09:00
eP.LB008	Screening of MPXV, VZV, HSV-1, and HSV-2 causing mucocutaneous vesicular rashes by multiplex HRM-PCR Nadege NZIZA TROUCHAUD (France)	09:00 - 09:00
eP.LB009	HDV in HIV/HBV Coinfection: Risk Factors, Prevalence, and 12-Year Mortality Outcomes Agnieszka Lembas (Poland)	09:00 - 09:00
eP.LB011	Evaluation of brain volume, brain age, and cognitive functions among people living with HIV in the era of effective antiretroviral therapy Müge Toygar Deniz (Turkey)	09:00 - 09:00
eP.LB012	Difference in five-year mortality risk among people living with HIV aged over 50, according to age at diagnosis, in a specialized clinic in Mexico City, CondeAging Cohort Humberto Gudiño Solorio (Mexico)	09:00 - 09:00
eP.LB013	Meaningful changes in [health-related] quality of life in people living with HIV in Nouvelle Aquitaine, France (2018-24): AQUIVIH-NA-QuAliv Study Wejden Yahyaoui (France)	09:00 - 09:00
eP.LB014	Estimation of the cost of complacency in the fight against HIV in Europe Helen Hayes (United Kingdom)	09:00 - 09:00
eP.LB016	Determinants of Successful Integration of Long-Acting Antiretroviral Therapy into Established HIV Clinics: Examining Barriers, Facilitators, and Implementation Strategies Clarence Soliman (Ireland)	09:00 - 09:00
eP.LB017	Beyond the 0.1% threshold: an economic evaluation of HIV indicator condition-based testing in hospital settings Klaske Vliegenthart-Jongbloed (The Netherlands)	09:00 - 09:00
eP.LB018	Analysis of the population and outcomes of individuals tested for HIV at voluntary counselling and testing points (VCTs) in Poland during the first three years of the armed conflict in Ukraine (2022-2024) Magdalena Ankiersztejn-Bartczak (Poland)	09:00 - 09:00
eP.LB019	Models of care for women living with HIV in Europe: a scoping review Duaa Rao (Germany)	09:00 - 09:00
eP.LB020	Assessing the Effectiveness of Integrating a Peer Educators Program in Enhancing HIV Services Uptake among students at Malawi University of Business and Applied Sciences, Blantyre, Malawi Billy Khembo (Malawi)	09:00 - 09:00

eP.LB021	Persistent HIV stigma and discrimination in family and medical settings. Findings from university medical center in Hamburg, Germany Anna Koval (Germany)	09:00 - 09:00
eP.LB022	Outcomes of HIV Care clients enrolled in enhanced personal contact intervention using mobile GIS-based Re-engagement APP to improve continuity in care in Lilongwe, Malawi. Petros P.M Tembo (Malawi)	09:00 - 09:00
eP.LB023	Mapping Vaccination Recommendations and Access to Vaccinations for People Living with HIV in Europe Emily Burzynski (Poland)	09:00 - 09:00
eP.LB024	Embedding a community-led mobile app within a national HIV digital ecosystem: the case of Moldova Constantin Cearanovski (Moldova)	09:00 - 09:00
eP.LB025	Global forecast on long-acting PrEP need and readiness across 172 countries: urgent equity and access gaps for key populations Micheal Ighodaro (United States)	09:00 - 09:00
eP.LB026	Women and PrEP: Gap Between Indication and Actual Use in France Jérémy ZEGGAGH (France)	09:00 - 09:00
eP.LB027	No woman left behind: scaling triple elimination of HIV, syphilis, and hepatitis B through community testing in informal settings in Southwest Nigeria Victor Aganaba (Nigeria)	09:00 - 09:00
eP.LB028	High acceptance among hospital attendees supports implementing hospital-wide HIV testing for indicator conditions Klaske Vliegthart-Jongbloed (The Netherlands)	09:00 - 09:00
eP.LB030	IASO (Innovation-Action-Health-Opportunity) program, acceptability and feasibility of screening for HIV and viral hepatitis as part of a collaborative 'outreach' global health project in migrant living areas Christia Palacios (France)	09:00 - 09:00
eP.LB031	Chemsex phenomenon in Andalusia: a cross-sectional study from the perspective of users and healthcare professionals Javier de la Torre Lima (Spain)	09:00 - 09:00
eP.LB032	Sexual health of men who have sex with men in Croatia: results of a biobehavioural survey using respondent-driven sampling with online recruitment and facility-based testing Josip Begovac (Croatia)	09:00 - 09:00
eP.LB033	Gendered Labor and Sex Work in Taiwan's Gig Economy: Sexual Health Information Needs, Sharing Practices, and Inequalities Chia-Wen Li (Taiwan)	09:00 - 09:00

Plenary lecture

09:15 - 09:45

GRAND AMPHITHEATRE

PL1 - Are we prepared for pandemics?

Sanjay Bhagani (United Kingdom)

Are we prepared for pandemics?

Yazdan Yazdanpanah (France)

09:15 - 09:45

Plenary lecture

09:45 - 10:20

GRAND AMPHITHEATRE

PL2 - ART now & near: how far have we come & how much further must we go?

Alexandra Calmy (Switzerland)

ART now & near: how far have we come & how much further must we go?

09:45 - 10:15

Monica Gandhi (United States)

ANRS Emerging Infectious Diseases (MIE) Award for the Best Basic Science Translational Paper

10:15 - 10:20

Yazdan Yazdanpanah (France)

Breaks

10:15 - 11:00

GRAND AMPHITHEATRE

Coffee break*Oral presentations*

10:45 - 12:00

ROOM 252AB

O1 - Oral cross track session

Nicola Mackie (United Kingdom)

Michaela Müller-Trutwin (France)

- | | | |
|---------|---|---------------|
| O1.1 | T-cell modulation following therapeutic vaccination in people living with HIV (PLWH)
Yunjoo Lee (United States) | 10:45 - 10:54 |
| O1.2 | Lymph nodes play a central role in SIV persistence compared to gut (P-VISCONTI study)
Véronique AVETTAND-FENOEL (France) | 10:54 - 11:03 |
| O1.3 | Mapping patterns of resistance to 2nd generation INSTI in clinical practice: results from the ROSETTA-registry
Mafalda N.S. Miranda (The Netherlands) | 11:03 - 11:12 |
| O1.4 | Association of Injection Site with Trough Concentrations of Cabotegravir and Rilpivirine Q2M
Thierry Prazuck (France) | 11:12 - 11:21 |
| O1.5 | Beyond COVID-19 in People with HIV: specific miRNA Expression Profile persists after SARS-CoV-2 clearance
Sergio Grande Garcia (Spain) | 11:21 - 11:30 |
| O1.6 | HIV is Associated with CT Measures of Interstitial Lung Disease: Analyses from the Multicenter AIDS Cohort Study
Sarath Raju (United States) | 11:30 - 11:39 |
| O1.7 | Health-related quality of life in ageing people with HIV is not different to that of well-matched controls without HIV: an 8-year longitudinal analysis from the AGE_{HIV} cohort study on ageing and comorbidities
Kevin Moody (The Netherlands) | 11:39 - 11:48 |
| O1.8.LB | Tracking HIV DNA fate in secondary lymphoid and hematopoietic organs during acute infection using a humanized mouse model
Jean Sebastien Diana (France) | 11:48 - 11:57 |

Parallel session

11:00 - 12:00

GRAND AMPHITHEATRE

PS01 - Integrase inhibitors everywhere: Good or bad?

Antonios Papadopoulos (Greece)

Christine Katlama (France)

	It always starts from scratch: Integrase resistance and its global implications	11:00 - 11:10
	Jonathan Schapiro (Israel)	
PS01.1	Potential treatment options following virological failure with long-acting injectable cabotegravir and rilpivirine: an analysis based on reported cases	11:10 - 11:19
	Maria Mazzitelli (Italy)	
PS01.2	Weight and Body Composition After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily from BIC/FTC/TAF in Adults Living With HIV-1: Week 48 Results From a Randomized, Double-Blind Phase 3 Study	11:19 - 11:28
	Chloe Orkin (United Kingdom)	
PS01.3	Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO Study)	11:28 - 11:37
	Arnau Monforte (Spain)	
PS01.4	Hepatitis B Virus Reactivation in People Living with HIV Switching to Long Acting-Cabotegravir/Rilpivirine therapy: A Cohort Study Analysis	11:37 - 11:46
	Alberto Foncillas (Spain)	

Parallel session

11:00 - 12:00

AMPHITHEATRE BORDEAUX

PS02 - Scaling up PrEP to meet the needs of everyone

Magdalena Ankiersztejn-Bartczak (Poland)

Claudia Estcourt (United Kingdom)

	The Why and the How of addressing PrEP equity across Europe	11:00 - 11:10
	Oana Sandulescu (Romania)	
	Meeting the PrEP needs of women	11:10 - 11:20
	Sinead Delany (South Africa)	
PS02.1	Extended PrEP cascades and determinants of long-acting PrEP intention and unmet PrEP needs among transgender women, transgender men, and non-binary individuals in 20 European countries	11:20 - 11:29
	Haoyi Wang (The Netherlands)	
PS02.2	Gaps and Gains in PrEP Continuity: Clinical and Programmatic Insights from Nigeria's 2024 National Rollout	11:29 - 11:38
	Ramatu Aliyu Magaji (Nigeria)	
PS02.3	Strengthening Community-Based Integrated HIV/STI/VH Prevention, Testing, and Linkage-to-Care: First-Year Outcomes of the CORE Project	11:38 - 11:47
	Laura Fernández-López (Spain)	
PS02.4	Recruitment of Disproportionately Affected Populations in the PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK	11:47 - 11:56
	Jean-Michel Molina (France)	

Parallel session

11:00 - 12:00

ROOM MAILLOT

PS03 - Senescence, inflammation and ageing in HIV. What is all the fuss about?

Cristina Mussini (Italy)

Paddy Mallon (Ireland)

	Ageing with HIV: from basic science to clinical research	11:00 - 11:15
--	---	---------------

	Georg Behrens (Germany)	
PS03.1	Associations between gut microbiome, kynurenine pathway of tryptophan metabolism, and symptoms of depression in people with HIV Xiangning Bai (Norway)	11:15 - 11:24
PS03.2	Immune-inflammatory profile with inflammation, innate activation, and endothelial dysfunction in people with HIV is associated with obstructive coronary artery disease Moises Alberto Suarez-Zdunek (Denmark)	11:24 - 11:33
PS03.3	A Randomized, Multi-Center, Double-Blind, Placebo-Controlled ACTG Study to Evaluate the Effects of Cenicriviroc on Arterial Inflammation in People with HIV Janet Lo (United States)	11:33 - 11:42
<i>Breaks</i>		
	12:00 - 14:30	GRAND AMPHITHEATRE
Lunch break		
<i>Industry sponsored session</i>		
	12:30 - 14:00	AMPHITHEATRE BLEU
Industry sponsored session		
<i>Special session</i>		
	12:30 - 13:30	AMPHITHEATRE BORDEAUX
SPS1 - WHO: From real promise to complex reality: implementation of WHO recommendations on long-acting PrEP in times of global health funding cuts		
Stela Bivol (Switzerland) Jean-Michel Molina (France)		
	Introduction	12:30 - 12:35
	WHO Recommendations on long-acting PrEP: from theory to practice Viatcheslav Grankov (Denmark)	12:35 - 12:50
	Panel discussion Denis Godlevskiy (Germany) Mila Maistat (Switzerland) Chris Obermeyer (Switzerland) Liudmyla Legkostup (Ukraine)	12:50 - 13:25
	Discussion/Q&A	13:25 - 13:30
<i>Special session</i>		
	12:30 - 13:30	ROOM MAILLOT
SPS2 - NEAT ID: LAPTOP: Late Presenters, the Science and the Impact		
Anton Pozniak (United Kingdom) Brenda Crabtree (Mexico)		
	Welcome and Introductions Esteban Martínez (Spain)	12:30 - 12:33
	NEAT ID: In Numbers, Background, and Structure Esteban Martínez (Spain)	12:33 - 12:38
	LAPTOP: Late Presenters, the Science and the Impact Georg Behrens (Germany)	12:38 - 12:58
	Discussion/Q&A	12:58 - 13:08

	NEAT ID: Study Updates, Recruitment, Grants and how to get involved	13:08 - 13:20
	Jürgen K Rockstroh (Germany) Nikos Dedes (Greece)	
	Presenting the NEAT ID Young Investigator of the Year with thanks to the Advisory Group Committee	13:20 - 13:30
	Jürgen K Rockstroh (Germany)	
<i>Parallel session</i>		
14:30 - 15:30		GRAND AMPHITHEATRE
PS04 - Social and gender inequities in accessing care and prevention		
Grzegorz Jezierski (Poland) Harriet Langanke (Germany)		
	Gender inequities	14:30 - 14:40
	Nathalie Bajos (France)	
	Intersectional stigma	14:40 - 14:50
	Bülent Turan (Turkey)	
PS04.1	Exploring Mental Health Burden in Adults who Acquired HIV during Childhood and Adolescence	14:50 - 14:59
	Beatriz Julieta Blanco Rojas (Spain)	
PS04.2	Economic Drivers of HIV Vulnerability Among African Refugee Male Sex Workers in Italy: A Mixed-Methods Study	14:59 - 15:08
	Marco Barracchia (The Netherlands)	
PS04.3	Multidimensional gender affirmation among transgender women living with HIV: an indicator of engaging in transactional sex?	15:08 - 15:17
	Raymond Van Huizen (France)	
PS04.4	Chemsex Substance Use among gbMSM in Switzerland, a Cohort Collaboration Study between the Swiss HIV Cohort Study and the SwissPrEPared Study	15:17 - 15:26
	Bashkim Jaha (Switzerland)	
<i>Parallel session</i>		
14:30 - 15:30		AMPHITHEATRE BLEU
PS05 - Hepatitis and TB Co-Infection		
Juan Berenguer (Spain) Aisuluu Bolotbaeva (Kyrgyzstan)		
	Risk and screening for Hepatocellular carcinoma in people with HIV	14:30 - 14:45
	Jürgen K Rockstroh (Germany)	
PS05.1	Hepatocellular Carcinoma Screening in HIV/HBV Coinfected Individuals: Insights from Spain, Germany, and Poland	14:45 - 14:54
	Juan Berenguer (Spain)	
PS05.2	Kinetics of occult hepatitis B infection in people with HIV switching from HBV-active ART to long-acting cabotegravir/rilpivirine	14:54 - 15:03
	Alessia Magnapera (Italy)	
PS05.3	Analysis of tuberculosis preventive treatment cascade among people living with HIV in the country of Georgia: a mixed methods study	15:03 - 15:12
	Mariana Buziashvili (Georgia)	
PS05.4	Evaluating Plasma Proteome Signatures for Active Tuberculosis Prediction and Immune Profiling in People With HIV	15:12 - 15:21
	Katharina Kusejko (Switzerland)	

Parallel session

14:30 - 15:30

AMPHITHEATRE BORDEAUX

PS06 - Cancer screening in people living with HIV: What's new?

Botond Lakatos (Hungary)

Lene Ryom (Denmark)

	Lung cancer screening	14:30 - 14:40
	Alain Makinson (France)	
	Cervical and anal cancer screening	14:40 - 14:50
	Mar Masià (Spain)	
PS06.1	Outcomes of cervical cancer screening among women with HIV in the Netherlands	14:50 - 14:59
	Vita Jongen (The Netherlands)	
PS06.2	Anal cancer screening in a cohort of women with HIV: uptake and outcome from a prospective study	14:59 - 15:08
	Maria Mazzitelli (Italy)	
PS06.3	Prostate Cancer in People Living with HIV (PLWH): Results from a Large Retrospective Multicentre Analysis in Germany	15:08 - 15:17
	Malte Benedikt Monin (Germany)	
PS06.4	Evolving cancer incidence in persons with HIV in France between 2014-2023: A nationwide study using the French National Health Data System	15:17 - 15:26
	Elhadji Leye (France)	

Parallel session

14:30 - 15:30

ROOM MAILLOT

PS07 - Innovative mechanisms shifting the paradigm of treatment and prevention

Elena Bruzzesi (Italy)

François Dabis (France)

	HIV Capsid Dynamics and Lenacapavir's Role in Remodeling Viral Replication	14:30 - 14:40
	Francesca Di Nunzio (France)	
	Perspectives of bNAbs and vaccine research	14:40 - 14:50
	Florian Klein (Germany)	
PS07.1	Safety and analytical treatment interruption outcomes in a clinical trial of 2 broadly neutralizing antibodies plus vesatolimod in early-treated South African women with clade C HIV-1	14:50 - 14:59
	Krista Dong (United States)	
PS07.2	Lenacapavir Directs Specific Immunoproteasome-Mediated Degradation of Gag Proteins and Increases the killing of HIV-Infected Cells	14:59 - 15:08
	Pierre Gantner (France)	
PS07.3	Dasatinib enhances NK cell cytotoxicity and reverses functional exhaustion in HIV infection	15:08 - 15:17
	María José Muñoz-Gómez (Spain)	
PS07.4.LB	Characterization of NK Cell Subsets and ADCC Function in a Case of Sustained HIV Remission after allogeneic stem cell transplantation (2nd Berlin Case)	15:17 - 15:26
	Timo Trenkner (Germany)	

Breaks

15:30 - 16:15

GRAND AMPHITHEATRE

Networking break

Industry sponsored session

16:15 - 17:15

AMPHITHEATRE BLEU

Industry sponsored session*Roundtable Discussion*

16:15 - 17:15

ROOM MAILLOT

RT2 - HBV reactivation in people living with HIV

Christoph Boesecke (Germany)

Risk of HBV reactivation in people living with HIV receiving NRTI sparing dual therapy

16:15 - 16:25

Tetiana Melnyk (France)

Roundtable Discussion on HBV reactivation in people living with HIV

16:25 - 17:15

Juan Berenguer (Spain)

Sanjay Bhagani (United Kingdom)

Karine Lacombe (France)

Special session

16:15 - 17:15

ROOM 252AB

SPS3 - EATG: HIV and other communicable diseases amid permacrisis: can Europe lead the way?

Christophe Martet (France)

Gus Cairns (United Kingdom)

Introduction: Epidemiology, surveillance and normative practice

16:15 - 16:25

Stela Bivol (Switzerland)

Roundtable discussion

16:25 - 17:05

Christoph Spinner (Germany)

Julia del Amo (Spain)

Remko van Leeuwen (The Netherlands)

Discussion/Q&A

17:05 - 17:15

Special session

16:15 - 17:15

ROOM 242AB

SPS4 - SFLS: Access to HIV care and prevention for migrants

Hugues Cordel (France)

Caroline Andoum (France)

Introduction

16:15 - 16:20

Migration as a social determinant of health and how to create safe places for health care

16:20 - 16:35

Ursula Trummer (Austria)

After 10 years of PrEP in France, is it effectively available for Migrants?

16:35 - 16:50

Nicolas Vignier (France)

The forgotten half of the equation: extending prenatal screening to Migrant future fathers

16:50 - 17:05

Pauline Penot (France)

Discussion/Q&A

17:05 - 17:15

Special session

17:30 - 18:30

GRAND AMPHITHEATRE

EACS Guidelines session

Jürgen K Rockstroh (Germany)

Juan Ambrosioni (Spain)

Part I

17:30 - 17:30

Antiretrovirals for treatment and prevention

17:30 - 17:40

Laura Levi (France)

Pediatric HIV

17:40 - 17:50

Paolo Paioni (Switzerland)

HIV Co-infections

17:50 - 18:00

Andrea Mastrangelo (Switzerland)

Part II

18:00 - 18:00

Co-morbidities

18:00 - 18:15

Abiu Sempere (Spain)

Jasmini Alagaratnam (United Kingdom)

Discussion

18:15 - 18:30

Alexandra Calmy (Switzerland)

Catia Marzolini (Switzerland)

Steven Welch (United Kingdom)

Cristiana Oprea (Romania)

Esterban Martínez (Spain)

Friday, October 17, 2025

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP13 - Knowledge and beliefs about HIV prevention strategies

Robert Hejzák (Czech Republic)

- | | | |
|---------|--|---------------|
| MeP13.1 | Unpacking Chemsex in Amsterdam: What Distinguishes Non-Users, Non-Problematic, and Problematic Users?
Dortje van den Dungen (The Netherlands) | 12:05 - 12:10 |
| MeP13.2 | Identification of Migrant Women's Care Needs and Barriers to HIV Testing - The SERAY Study
Giota Lourida (Greece) | 12:10 - 12:15 |
| MeP13.3 | Barriers to tobacco smoking cessation support during hospital follow-up of adult people living with HIV/AIDS: a clinicians' perspective
Fabienne Marcellin (France) | 12:15 - 12:20 |
| MeP13.4 | Perceived neurocognitive impairment is associated with levels of depression and quality of life in adults seeking memory rehabilitation for HIV associated neurocognitive disorders (HAND)
Signe Andersen (France) | 12:20 - 12:25 |

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP17 - Viruses establishing infection and Vaccines

Antonella Castagna (Italy)

- | | | |
|---------|--|---------------|
| MeP17.1 | Genetic and functional characteristics of CXCR4-using viral envelope glycoproteins in acute HIV-1 infection
Dorine Martres (France) | 14:05 - 14:10 |
| MeP17.2 | Identification of a broad and potent V3 glycan site bNAb targeting an N332_{gp120} glycan-independent epitope
Malena Rohde (Germany) | 14:10 - 14:15 |
| MeP17.3 | Safety of a ChAdOx1.tHIVconsvX prime - MVA.tHIVconsvX boost vaccination regimen in people with HIV treated in primary infection: a phase I/II randomized, placebo-controlled trial (HIV-CORE 007)
Elena Bruzzesi (Italy) | 14:15 - 14:20 |
| MeP17.4 | Assessment of the specific cellular immune response to the recombinant Herpes Zoster vaccine in people living with HIV
Grazia Alessio (Italy) | 14:20 - 14:25 |

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP21 - Cabotegravir and rilpivirine in real world

Silvia Nozza (Italy)

- | | | |
|---------|--|---------------|
| MeP21.1 | Pharmacokinetics and safety data after switching from injectable cabotegravir (CAB) + rilpivirine (RPV) to oral bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Priyanka Arora (United States) | 15:35 - 15:40 |
| MeP21.2 | Comparable efficacy, but increased adverse events and treatment-emergent resistance with injectable cabotegravir/rilpivirine compared to standard oral antiretroviral therapy: two systematic reviews and meta-analyses | 15:40 - 15:45 |

	Cassandra Fairhead (United Kingdom)	
MeP21.3	Impact of liver fibrosis on cabotegravir and rilpivirine long-acting plasma concentrations Caterina Candela (Italy)	15:45 - 15:50
MeP21.4	Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV-1 Alexandra Calmy (Switzerland)	15:50 - 15:55
MeP21.5	Antiretroviral Switch and Weight Gain: Cardiometabolic Implications of Switching to Darunavir/Cobicistat + Lamivudine José Antonio Mata Marín (Mexico)	15:55 - 16:00
MeP21.6	Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living with HIV in Spain: A Substudy of the RELATIVITY Cohort Jara Llenas-García (Spain)	16:00 - 16:05
MeP21.7	Determinants of Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A Cause-Specific Analysis from Real-World Data Miguel Torralba (Spain)	16:05 - 16:10

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP14 - Innovative and Integrated Approaches to HIV Prevention and Care

Constance Delaugerre (France)

MeP14.1	Evaluating the Impact of Integrating HIV Pre-Exposure Prophylaxis (PrEP) into Routine Health Insurance in Switzerland: A Mixed-Methods Analysis Andrea Farnham (Switzerland)	12:05 - 12:10
MeP14.2	High PrEP Uptake Among Men Who Have Sex with Men (MSM) Recruited Via Digital and Physical Community-Led Outreach in Paris, France Anton Eremin (France)	12:10 - 12:15
MeP14.3	Working with Mentor Mothers as an Implementation Strategy for Supporting Perinatal Mental Health of Kenyan Women Living with HIV Janet Turan (United States)	12:15 - 12:20
MeP14.4	Integration of geriatric concepts into HIV care structures: a single-center pilot study in Dakar Alassane NDIAYE (Senegal)	12:20 - 12:25

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP18 - Mind the Gaps: Socio-demographic Disparities, Resistance, and HIV Elimination Pathways

Sophie Grabar (France)

MeP18.1	2023 HIV Cascade of care by specific groups in the Québec HIV Cohort Alexandra de Pokomandy (Canada)	14:05 - 14:10
MeP18.2	Targeting the Gaps: Testing Trends and Intersectional Analysis of HIV Testing Among Women Across Key Populations (2017-2023) in the COBATEST Network Laura Fernández-López (Spain)	14:10 - 14:15

MeP18.3 **Harnessing national registry data to identify socio-demographic and socio-economic gaps in HIV care in the Netherlands** 14:15 - 14:20
Vita Jongen (The Netherlands)

MeP18.4 **Impact of continental spread of HIV-1 integrase resistance on progress toward the WHO's 2030 elimination goals** 14:20 - 14:25
Victor Pimentel (Portugal)

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP22 - Screening for Comorbidities

Casper Rokx (The Netherlands)

MeP22.1 **Systematic screening for age-related comorbidities: health care optimization among individuals living with HIV in the out-patient clinic in Copenhagen, Denmark** 15:35 - 15:40
Anna Katrine Haslund Roed (Denmark)

MeP22.2 **Evolving dynamics with prolonged life expectancy: The cancer profile in people living with HIV** 15:40 - 15:45
inci Yilmaz Nakir (Turkey)

MeP22.4 **Missed opportunities for anal cancer screening in women living with HIV: results from a survey across the European Region** 15:50 - 15:55
Dagny Krankowska (Poland)

MeP22.5 **Prevalence and Risk Factors of Frailty Among Japanese People with HIV: Implications for Health-Related Quality of Life** 15:55 - 16:00
Hideta Nakamura (Japan)

MeP22.6 **Long Term Trends For Bone Mineral Density and Trabecular Bone Scores In Men Living With and Without HIV: Impact of Tenofovir Disoproxil Fumarate Exposure** 16:00 - 16:05
Henning Drechsler (United States)

MeP22.7 **Screening for bone health in older people with HIV: uptake and outcomes from a large UK outpatient HIV service** 16:05 - 16:10
Rhys Nicholas (United Kingdom)

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP15 - Clinical Cases - Complex Presentations and Co-Infections in Advanced HIV

Monika Bociaga-Jasik (Poland)

MeP15.C1 **Disseminated histoplasmosis and CMV ileocolitis in a late presenter with advanced HIV and IRIS** 12:05 - 12:10
Alexy Inciarte Portillo (Spain)

MeP15.C2 **Prophylaxis failure or IRIS reality? A case of unmasking *Mycobacterium avium* complex (MAC)-associated IRIS** 12:10 - 12:15
Nikolaos Mazonakis (Greece)

MeP15.C3 **Disseminated Kaposi sarcoma as initial AIDS-defining illness in a transgender woman with advanced HIV: mucocutaneous, pulmonary, gastrointestinal and nodal involvement** 12:15 - 12:20
Alberto Foncillas (Spain)

MeP15.C4 **Disseminated cryptococcosis and pneumocystosis as a rare and unusual presentation of primary HIV infection: case report and literature insights** 12:20 - 12:25
Lorenzo Ciullini (Switzerland)

Moderated ePosters

14:05 - 14:25

ePoster Exhibition

MeP19 - Beyond with DTG/3TC

Silvia Nozza (Italy)

MeP19.1	“Leaving no stones unturned”: 10 years results on the tolerability and metabolic safety of DTG+3TC as a switch regimen Arturo Ciccullo (Italy)	14:05 - 14:10
MeP19.2	Switching to dolutegravir/lamivudine is non-inferior to continuing triple-drug ART in virologically suppressed people with HIV: 2 year results of the DUALING prospective matched nationwide clinical practice study Casper Rokx (The Netherlands)	14:10 - 14:15
MeP19.3	Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort Arturo Ciccullo (Italy)	14:15 - 14:20
MeP19.4	48-WEEK RESULTS OF SWITCHING FROM DTG/3TC TO BIC/FTC/TAF IN PWH AND NEUROPSYCHIATRIC COMORBIDITIES Ignacio Perez Valero (Spain)	14:20 - 14:25

Moderated ePosters

15:35 - 16:10

ePoster Exhibition

MeP23 - Clinical Cases - Diagnostic Dilemmas, Immunologic Mysteries & ART Challenges

Botond Lakatos (Hungary)

MeP23.C.1	ART switch challenges: hepatitis B reactivation in people living with HIV & HBV co-infection and longstanding HBsAg loss Flora Olcott (United Kingdom)	15:35 - 15:40
MeP23.C.2	Management of HIV-related Progressive Multifocal Leukoencephalopathy: insights from metagenomic next-generation diagnosis and pembrolizumab-lenalidomide therapy, a case report Yongzheng Guo (China)	15:40 - 15:45
MeP23.C.3	A challenging diagnosis of VEXAS syndrome in a person living with HIV: a case of recurrent systemic inflammation and cytopenia Buse Kenanoglu (Turkey)	15:45 - 15:50
MeP23.C.4	Hemophagocytic lymphohistiocytosis in HIV: a diagnostic and therapeutic challenge highlighted by a rapidly fatal case Banu Çiçek Aktaş (Turkey)	15:50 - 15:55
MeP23.C.5	Recurrent fever of unknown origin in a patient with advanced HIV-2 infection: think beyond infectious diseases Dara Mbanze (Portugal)	15:55 - 16:00
MeP23.C.6	Unusual HIV seroconversion in PrEP user carrying heterozygous CCR5-Delta32 mutation: did he contract HIV? Hélène Laroche (France)	16:00 - 16:05
MeP23.C.7	The Dancer, the Cave, and the Squatters Alberto Díaz-de Santiago (Spain)	16:05 - 16:10

Moderated ePosters

12:05 - 12:25

ePoster Exhibition

MeP16 - Practical implementation of novel PrEP modalities

Nicolas Nagot (France)

MeP16.1	Commonly Prescribed Concomitant Medications and Clinical Safety Findings With Lenacapavir for Pre-Exposure Prophylaxis in	12:05 - 12:10
---------	--	---------------

PURPOSE 2		
	Anchalee Avihingsanon (Thailand)	
MeP16.2	The Potential Impact of Twice-Yearly Injectable Lenacapavir Among Cisgender Gay, Bisexual, and Other Men Who Have Sex With Men (GBMSM) and Other Priority HIV Prevention Populations (Transgender People and Highly Exposed Heterosexual People) in France Henri Leleu (France)	12:10 - 12:15
MeP16.3	Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men who have sex with men in a European country Philip Wikman-Jorgensen (Spain)	12:15 - 12:20
MeP16.4	Evaluation of the completion rate and associated factors in HIV-Post-Exposure Prophylaxis regimen containing Doravirine (DORASPEP): a prospective observational cohort Romuald Cruchet (France)	12:20 - 12:25
<i>Moderated ePosters</i> 14:05 - 14:25		
		ePoster Exhibition
MeP20 - Prevention and HIV testing - innovative approaches and access Nicolas Nagot (France)		
MeP20.1	A novel way to improve access to Pre-Exposure Prophylaxis (PrEP) in the community via primary care Rachel Kirby (United Kingdom)	14:05 - 14:10
MeP20.2	Comparative benefits of pre-exposure prophylaxis versus test-and-treat to reduce community viral load: a systematic review of PrEP trials Cassandra Fairhead (United Kingdom)	14:10 - 14:15
MeP20.3	Randomized controlled clinical pilot study to evaluate the feasibility and acceptability of a telemedicine approach for HIV prevention with HIV Pre-Exposure Prophylaxis versus standard of care in Germany Florian Voit (Germany)	14:15 - 14:20
MeP20.4.LB	Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals Kimberley Brown (United States)	14:20 - 14:25
<i>Moderated ePosters</i> 15:35 - 16:10		
		ePoster Exhibition
MeP24 - HIV Infection and Coinfection: Trends, Risks, and treatment Charles Béguelin (Switzerland)		
MeP24.1	Differences in ART regimen initiation among people with recently acquired HIV: 2015-2021 Fiona Burns (United Kingdom)	15:35 - 15:40
MeP24.2	Elite controllers in a cohort of people with well-estimated dates of HIV seroconversion: characteristics, time to lose elite status and natural CD4 evolution Nikos Pantazis (Greece)	15:40 - 15:45
MeP24.3	Increasing prevalence of highly viremic persons diagnosed with chronic HIV infection: data from the ICONA cohort study Antonella d'Arminio Monforte (Italy)	15:45 - 15:50

MeP24.4	Epidemiology of HIV infection and HIV/HCV coinfection in marginalized populations of Madrid (2019-2023) Jorge Valencia La Rosa (Spain)	15:50 - 15:55
MeP24.5	Declining HIV incidence in MSM diagnosed with syphilis: a retrospective longitudinal study Maria Gabriella Donà (Italy)	15:55 - 16:00
MeP24.6	Coverage and determinants of prenatal screening for HIV, syphilis and hepatitis B: a cross-sectional survey in Burkina Faso and The Gambia (TRI-MOM project) Vincent Di Beo (France)	16:00 - 16:05
MeP24.7	Integrated cervical cancer - high-risk human papillomavirus testing - screening strategy with other sexually transmitted infections offered to vulnerable women far from health facilities. Pilot intervention with sex-working women in Paris, France and Yerevan, Armenia Marc SHELLY (France)	16:05 - 16:10

Industry sponsored session

08:00 - 09:00

AMPHITHEATRE BLEU

Industry sponsored session*Meet-the-expert*

08:00 - 09:00

AMPHITHEATRE BORDEAUX

MTE3 - Invisible Battles: Mental and Neurological Health**HIV-Related Brain Injury in 2025: Evolving Diagnosis and Treatment**

08:00 - 08:10

Paola Cinque (Italy)

Mental health challenges in people living with HIV

08:10 - 08:20

Jordi Blanch (Spain)

Interactive discussion with the audience

08:20 - 09:00

Meet-the-expert

08:00 - 09:00

ROOM MAILLOT

MTE4 - Should we have ATI trials and how?

Sarah Fidler (United Kingdom)

Beatriz Mothe (Spain)

Krista Dong (United States)

RIO trial participant testimony

08:00 - 08:05

Johan Marais (United Kingdom)

MTE4.1

Qualitative Insights into the Lived Experiences of People living with HIV who Participated in an Analytical Treatment Interruption in the RIO Randomised-Controlled Trial

08:05 - 08:14

Jesal Gohil (United Kingdom)

Interactive discussion with the audience

08:14 - 08:50

Meet-the-expert

08:00 - 09:00

ROOM 242AB

MTE5 - Weighing in on weight gain

Esteban Martínez (Spain)

What does the data really tell us on weight gain in people living with HIV?

08:00 - 08:10

Dominique Costagliola (France)

Therapeutic options for losing weight: GLP -1 receptor agonists and what else?

08:10 - 08:20

Paddy Mallon (Ireland)

ePosters

09:00 - 18:00

ePoster Exhibition

ePosters on Display

Plenary lecture

09:15 - 09:45

GRAND AMPHITHEATRE

PL3 - "Five years left!" What targets are in reach in Europe and which will we struggle to make?

Cristiana Oprea (Romania)

"Five years left!" What targets are in reach in Europe and which will we struggle to make?

09:15 - 09:45

Teymur Noori (Sweden)

Plenary lecture

09:45 - 10:20

GRAND AMPHITHEATRE

PL4 - HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies

Justyna Kowalska (Poland)

HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies

09:45 - 10:15

Jeanne Sibiude (France)

NEAT-ID: The Anton Pozniak Award for Best Clinical/Epidemiological Paper

10:15 - 10:20

Anton Pozniak (United Kingdom)

Breaks

10:15 - 11:00

GRAND AMPHITHEATRE

Coffee break

Oral presentations

10:45 - 12:00

ROOM 252AB

O2 - Oral cross track session

David Jilich (Czech Republic)

Annette Haberl (Germany)

O2.1

Review of HIV and Breastfeeding Guidelines Across Europe: Insights from the WAVE Survey 'Same, same, but different: European Guidelines on HIV and breastfeeding'

10:45 - 10:54

Lila Haberl (Germany)

O2.2

Long-acting injectable cabotegravir/rilpivirine in young adults with perinatally acquired HIV. RELATIVITY cohort study

10:54 - 11:03

Jose I Bernardino (Spain)

O2.3

Impact of a revised late HIV diagnosis definition on late HIV estimates in Europe: A multi-country pilot study

11:03 - 11:12

Peter Kirwan (United Kingdom)

O2.4

Estimating HIV incidence and number of people with undiagnosed HIV in the European Union/European Economic Area in 2023

11:12 - 11:21

Ard van Sighem (The Netherlands)

O2.5

Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to

11:21 - 11:30

	2024	
	Rozenn Esvan (Italy)	
O2.6	Comparison of the Time to Reach Viral Suppression after ART Initiation Between Transgender Women and Other PWH in France: Results from the ANRS CO4 FHDH	11:30 - 11:39
	Juliette Hemery (France)	
O2.7	Analysis of barriers to testing for HIV prevention and linkage to care among migrants in Europe	11:39 - 11:48
	Denis Onyango (United Kingdom)	
O2.8.LB	Incorporating migration dynamics in the CD4 back-calculation method for HIV incidence estimation	11:48 - 11:57
	Peter Kirwan (United Kingdom)	
<i>Parallel session</i>		
11:00 - 12:00		GRAND AMPHITHEATRE
PS08 - HIV Prevention: Current modalities and Future Horizons		
Sheena McCormack (United Kingdom)		
Šime Zekan (Croatia)		
	HIV testing, PEP and Partner Notification	11:00 - 11:10
	Fiona Burns (United Kingdom)	
PS08.1	“TelePrEP” - An online program for the delivery of remote PrEP services	11:10 - 11:19
	Maria Luisa Cosmaro (Italy)	
PS08.2	Intention to use long-acting injectable Pre-Exposure Prophylaxis among Belgian men who have sex with men - results of an online survey	11:19 - 11:28
	Thijs Reyniers (Belgium)	
PS08.3	Tolerability and Safety of Long-Acting Cabotegravir for HIV Pre-Exposure Prophylaxis: preliminary data from a multicenter prospective observational study	11:28 - 11:37
	Davide Moschese (Italy)	
PS08.4	Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan	11:37 - 11:46
	Angelo Roberto Raccagni (Italy)	
PS08.5	Annual Persistence to Twice-Yearly Lenacapavir Versus Daily Oral F/TDF for PrEP in the PURPOSE 2 Trial	11:46 - 11:55
	Onyema Ogbuagu (United States)	
<i>Parallel session</i>		
11:00 - 12:00		AMPHITHEATRE BORDEAUX
PS09 - New drugs in the pipeline		
Gordana Dragović (Serbia)		
Caroline Solas (France)		
	New HIV drugs: virological and pharmacological mechanisms	11:00 - 11:10
	Anne-Genevieve Marcelin (France)	
PS09.1	Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study	11:10 - 11:19
	Peter Leone (United States)	
PS09.2	Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results	11:19 - 11:28
	Onyema Ogbuagu (United States)	

PS09.3 **A French national real-world observatory of people initiating a lenacapavir-based treatment during the post-approval period** 11:28 - 11:37
Charlotte Charpentier (France)

PS09.4 **Fostemsavir in a real-world setting: over one year of data from the PRESTIGIO Registry** 11:37 - 11:46
Rebecka Papaioannu Borjesson (Italy)

Parallel session

11:00 - 12:00

ROOM MAILLOT

PS10 - How can AI be used to advance in HIV prevention, treatment and care?

Jens D. Lundgren (Denmark)

Dan Turner (Israel)

How can AI be used to advance in HIV prevention, treatment and care? 11:00 - 11:10

Rodolphe Thiébaud (France)

AI use in HIV prevention, case finding and early treatment uptake in Eastern Europe and Central Asia 11:10 - 11:20

Tetiana Deshko (Ukraine)

PS10.1 **Artificial Intelligence Meets HIV Education: Comparing Three Large Language Models on Accuracy, Readability, and Reliability** 11:20 - 11:29

Özge Eren Korkmaz (Turkey)

PS10.2 **A machine learning-based prognostic algorithm for serious non-aids events after initiation of antiretroviral therapy** 11:29 - 11:38

Giota Touloumi (Greece)

PS10.3 **Identifying patterns of low-level viremia with increased risk of subsequent viral failure using machine learning** 11:38 - 11:47

Katharina Kusejko (Switzerland)

Breaks

12:00 - 14:30

GRAND AMPHITHEATRE

Lunch break*Industry sponsored session*

12:30 - 14:00

AMPHITHEATRE BLEU

Industry sponsored session*Oral presentations*

12:30 - 13:30

AMPHITHEATRE BORDEAUX

RO1 - Mpox - from prevention to clinics

Ole Kirk (Denmark)

Chloe Orkin (United Kingdom)

RO1.1 **What is the impact of MVA-BN vaccine among people living with HIV in Israel?** 12:30 - 12:37

Zohar Mor (Israel)

RO1.2 **Smallpox Vaccine Reduces Mpox Disease Severity and Symptoms** 12:37 - 12:44

Christoph Boesecke (Germany)

RO1.3 **Immune profiling reveals hyperinflammatory signature in acute Mpox infection** 12:44 - 12:51

Joanne Byrne (Ireland)

RO1.4 **Single-Cell RNA Sequencing of Mpox Lesions Reveals Tissue-Resident Memory T Cell Dynamics and Replenishment in the Skin** 12:51 - 12:58

	Simona Saluzzo (Austria)	
RO1.5	Systematic molecular screening for mpox in anal/pharyngeal swabs in high-risk MSM on PrEP: a substudy of the ANRS-DOXYVAC trial Jade Ghosn (France)	12:58 - 13:05
RO1.6	Breakthrough mpox cases among different vaccination routes and under distinct HIV status Igor Moraes-Cardoso (Spain)	13:05 - 13:12
RO1.7	Disproportionate presentation of Mpox among people with HIV: A multicenter retrospective cohort study in Taiwan Andrew Po-Liang Chen (Taiwan)	13:12 - 13:19
RO1.8.LB	Mpox-related hospitalization and morbidity in people living with HIV and PrEP users: results from the European MASH-1 cohort study Nicolo Girometti (United Kingdom)	13:19 - 13:26

Oral presentations

12:30 - 13:30

ROOM MAILLOT

RO2 - Advancing prevention and care: insights from providers and perspectives from the community

Casper Rokx (The Netherlands)

Magdalena Ankiersztejn-Bartczak (Poland)

RO2.1	The jasmine project: revolutionary digital solutions to prevent violence and HIV among sex workers in France Brunna de Medeiros (France)	12:30 - 12:37
RO2.2	Profiles and follow-up of cis women using HIV pre-exposure prophylaxis (PrEP) Karen Champenois (France)	12:37 - 12:44
RO2.3	Expanding PrEP Access in France: Clinical Challenges and Community Perspectives from the QualiPrEP Study Daniela Rojas Castro (France)	12:44 - 12:51
RO2.4	More HIV pre-exposure prophylaxis options expected to increase overall use among Toronto sexual minority men: Projections from a discrete choice experiment Darrell H. S. Tan (Canada)	12:51 - 12:58
RO2.5	The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC Cassidy A Gutner (United States)	12:58 - 13:05
RO2.6	Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers' perspectives and experiences Clea Tanner (United Kingdom)	13:05 - 13:12
RO2.7	More Than Undetectable: Addressing Psychosocial Needs and Community Support Joanna Cano-Smith (Spain)	13:12 - 13:19
RO2.8.LB	Doxycycline prophylaxis to prevent bacterial STIs: Results of the open-label extension phase of the ANRS 174 DOXYVAC trial Jean-Michel Molina (France)	13:19 - 13:26

Oral presentations

12:30 - 13:30

ROOM 252AB

RO3 - Progress in clinical care

Clotilde Allavena (France)

Mojca Maticic (Slovenia)

RO3.1	Association Between Upregulated IL32 Expression and Inflammatory Patterns in Treated People with HIV Dana Alalwan (Ireland)	12:30 - 12:37
RO3.2	HPV-16 Clearance at the Anal Site in MSM with HIV: Impact of Immunization and Host Immune Status Elena Bruzzesi (Italy)	12:37 - 12:44
RO3.3	Implementation of EACS 2023 Cardiovascular Prevention Guidance in a Real-Life HIV Metabolic Clinic: A Longitudinal Cohort Study from Modena Marcella Manicardi (Italy)	12:44 - 12:51
RO3.4	LDL Target Achievement in people with HIV Over 40: Impact of Updated EACS Guidelines Giorgia Carrozzo (Italy)	12:51 - 12:58
RO3.5	Advancing HIV Care in Pregnancy: Trends in Virological Suppression, Mother-to-Child Transmission, and Postpartum Retention Over Two Decades Federica Casari (Italy)	12:58 - 13:05
RO3.7	Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: A substudy of the RELATIVITY cohort María José Galindo Puerto (Spain)	13:05 - 13:12
RO3.8.LB	Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial Esteban Martínez (Spain)	13:12 - 13:19

Parallel session

14:30 - 15:30

GRAND AMPHITHEATRE

PS11 - Emerging Challenges and Opportunities in STI Screening and Management

Jade Ghosn (France)

Monika Bociąga-Jasik (Poland)

	Should we screen for asymptomatic STI in MSM on PrEP? Charles Cazanave (France)	14:30 - 14:40
	Key questions and evidence gaps in the implementations of Doxyep Fiona Lyons (Ireland)	14:40 - 14:50
PS11.1	Bacterial STIs incidence among MSM with HIV in France: the ANRS PRIMO cohort Sophie Novelli (France)	14:50 - 14:59
PS11.2	Clinical Features of Syphilis in MSM on Doxycycline Post-Exposure Prophylaxis (doxy-PEP): Real-World Data from a Single-Center Cohort Cristina Gómez-Ayerbe (Spain)	14:59 - 15:08
PS11.3	Bacterial Sexually Transmitted Infections over a 4-year-period of follow-up in MSM on PrEP enrolled in the prospective ANRS-PREVENIR cohort Jade Ghosn (France)	15:08 - 15:17

Parallel session

14:30 - 15:30

AMPHITHEATRE BLEU

PS12 - Innovations, personalised medical services and social impacts

Daniela Rojas Castro (France)

Ben Collins (United Kingdom)

	Personalised medical approaches - is it the best approach to end the epidemic?	14:30 - 14:45
	Udi Davidovich (The Netherlands)	
PS12.1	Public Knowledge, Views, Perceptions and Attitudes towards HIV and People with HIV in Europe - Combined Results of an HIV Public Opinion Survey Conducted in 11 European Countries	14:45 - 14:54
	Konstantinos Protopapas (Greece)	
PS12.2	Risk of Income Loss in People Living With and Without HIV - a Comparative Swedish Nationwide Study Between 2019 to 2021	14:54 - 15:03
	Isabela Killander Möller (Sweden)	
PS12.3	Self-Reported Wellbeing and Integration Levels of Migrants with HIV in Italy: A Cross-Sectional Analysis from the ICONA Cohort	15:03 - 15:12
	Andrea Giacomelli (Italy)	
PS12.4	Transgender People with HIV in Italy: Higher Risk of Disengagement from Care and Adverse Outcomes in the ICONA Cohort	15:12 - 15:21
	Davide Moschese (Italy)	

Parallel session

14:30 - 15:30

AMPHITHEATRE BORDEAUX

PS13 - Ensuring access to HIV prevention and care for migrant populations in Europe

Deniz Gökengin (Turkey)

Tetiana Melnyk (France)

	The new EU framework for migration and its potential impact on migrant health	14:30 - 14:40
	Denis Onyango (United Kingdom)	
	Post-migration HIV acquisition in migrants receiving HIV care in Europe	14:40 - 14:50
	Romain Palich (France)	
PS13.1	Community-Based Screening for HIV and Viral Hepatitis Using Dried Blood Spots in a Migrant Population in Spain: the HEPINMIGRA study	14:50 - 14:59
	Jara Llenas-García (Spain)	
PS13.2	Seroprevalence of HIV, HBV, HCV, and Syphilis Among Syrian Refugees in Istanbul: Results from a Population-Based Prospective Study	14:59 - 15:08
	Asuman İnan (Turkey)	
PS13.3	The Impact of War on HIV and TB Epidemics in Ukraine: Challenges in Detection, Late Presentation, and Disease Burden	15:08 - 15:17
	Tetiana Koval (Ukraine)	
PS13.4	The impact of Russia's war in Ukraine on opioid agonist treatment (OAT) services, a primary HIV prevention strategy among people who inject drugs (PWID)	15:17 - 15:26
	Daniel J. Bromberg (United States)	

Parallel session

14:30 - 15:30

ROOM MAILLOT

PS14 - HIV-exposed uninfected children: A topic of clinical significance?

Karoline Aebi-Popp (Switzerland)

Mariana Mardarescu (Romania)

PS14.1

Outcomes of HIV-Exposed Uninfected Children Born to HIV-Positive Mothers at Bichat-Claude Bernard Hospital: The ENIVIH Study

14:30 - 14:39

ANTOINE Bachelard (France)

PRO

14:39 - 14:54

Claire Thorne (United Kingdom)

CON

14:54 - 15:09

Pablo Rojo (Spain)

Discussion

15:09 - 15:30

Breaks

15:30 - 16:15

GRAND AMPHITHEATRE

Networking break*Special session*

16:15 - 17:15

AMPHITHEATRE BLEU

SPS5 - ANRS: Global public health funding cuts: a new challenge for HIV in Africa?

Soufia Bham (Senegal)

Yazdan Yazdanpanah (France)

Introduction

16:15 - 16:20

Europe's response to support research & innovation in Africa and maximize the EU's attractiveness for scientific excellence

16:20 - 16:25

Michael Makanga (Belgium)

Modelling the potential impact of US government financial support withdrawal in Africa

16:25 - 16:30

Romain Silhol (United Kingdom)

Real life impact of financial cuts decisions on people and communities: case of Burundi

16:30 - 16:35

Jeanne Gapiya (Burundi)

Future-proofing HIV care in South Africa and beyond, amid a changing funding landscape

16:35 - 16:40

Harsha Somaroo (South Africa)

Roundtable discussion/Q&A

16:40 - 17:10

Special session

16:15 - 17:15

AMPHITHEATRE BORDEAUX

SPS6 - University of Liverpool Drug Interaction Team: Pharmacology of antiretrovirals in special populations

Saye Khoo (United Kingdom)

Catia Marzolini (Switzerland)

Introduction

16:15 - 16:20

Optimising treatment: the mind matters

16:20 - 16:35

Jordi Blanch (Spain)

TB treatment: more or less?

16:35 - 16:50

Gerry Davis (United Kingdom)

	Case on adolescents living with HIV	16:50 - 17:05
	Paolo Paioni (Switzerland)	
	Discussion/Q&A	17:05 - 17:15
<i>Roundtable Discussion</i>		
16:15 - 17:15		ROOM MAILLOT
	RT3 - HIV related stigma in healthcare settings - What next?	
	Teymur Noori (Sweden)	
	Setting the stage	16:15 - 16:25
	Katie Darling (Switzerland)	
	Roundtable Discussion on HIV related stigma in healthcare settings - What next?	16:25 - 17:15
	Ricardo Fernandes (Portugal)	
	Florence Thune (France)	
	Joseph Larmarange (France)	
	Dorthe Raben (Denmark)	
	Esteban Martínez (Spain)	
<i>Special session</i>		
16:15 - 17:15		ROOM 252AB
	SPS7 - ESCMID STI Study Group (ESTISG) and Sexually Transmitted Infections (STI) journal: 2025 Update on gonorrhea	
	Anna Maria Geretti (United Kingdom)	
	Justyna Kowalska (Poland)	
	Introduction	16:15 - 16:20
	What is the best approach to screen for gonorrhea	16:20 - 16:35
	Thibaut Vanbaelen (Belgium)	
	Current status of AMR in <i>N. gonorrhoeae</i> and new challenges	16:35 - 16:50
	Ismail Maatouk (Switzerland)	
	Where are we with OMV vaccines for gonorrhea ?	16:50 - 17:05
	Jean-Michel Molina (France)	
	Discussion/Q&A	17:05 - 17:15
<i>Meet-the-expert</i>		
16:15 - 17:15		ROOM 242AB
	MTE6 - The Rationale behind Remnants and Replication: Managing low-level viremia	
	Huldrych Günthard (Switzerland)	
	Annemarie Wensing (The Netherlands)	
MTE6.1	Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era	16:15 - 16:24
	Tommaso Clemente (Italy)	
	Interactive discussion with the audience	16:24 - 17:15

Saturday, October 18, 2025

Roundtable Discussion

08:00 - 09:00

AMPHITHEATRE BORDEAUX

RT4 - Guidelines versus Gospels (Guidelines, Evidence, and Reality)

Pierre Delobel (France)

Roundtable Discussion on "Guidelines versus Gospels (Guidelines, Evidence, and Reality)"

08:00 - 09:00

Iain Reeves (United Kingdom)

Juan Ambrosioni (Spain)

Dagny Krankowska (Poland)

Parallel session

09:15 - 10:15

AMPHITHEATRE BORDEAUX

PS15 - Co-Chairs Choice

Milosz Parczewski (Poland)

Karine Lacombe (France)

Jean-Michel Molina (France)

Bruno Spire (France)

- | | | |
|-----------|---|---------------|
| PS15.1 | Trends and Timing of HIV Diagnoses Among Migrants: A 15-Year Analysis from the Swiss HIV Cohort Study
Jessy J. Duran Ramirez (Switzerland) | 09:15 - 09:24 |
| PS15.2 | Doxycycline postexposure prophylaxis and the 4-component meningococcal B vaccine among persons living with HIV at high risk for bacterial sexually transmitted infections in Switzerland
David Wimmersberger (Switzerland) | 09:24 - 09:33 |
| PS15.3 | Chemsex, novel chemsex substances, associated risks for STIs, and an extended PrEP cascade among HIV-negative MSM, trans* individuals in 20 European countries: A latent class analysis
Kai J Jonas (The Netherlands) | 09:33 - 09:42 |
| PS15.4 | Metabolic and Body Composition Outcomes at 48 Weeks among People with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide Switching to Doravirine with or without Tenofovir Disoproxil Fumarate: ACTG A5391 (the DO-IT Trial)
John Koethe (United States) | 09:42 - 09:51 |
| PS15.5.LB | Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study
Amy Colson (United States) | 09:51 - 10:00 |
| PS15.6.LB | Low risk of HBV reactivation in HBcAb-positive/HBsAg-negative persons with HIV switching to non-tenofovir-based antiretroviral therapy
Lorin Bégré (Switzerland) | 10:00 - 10:09 |

Breaks

10:15 - 10:45

AMPHITHEATRE BORDEAUX

Coffee break*Special session*

10:45 - 11:30

AMPHITHEATRE BORDEAUX

SPS8 - EuroTest special session: Blood borne virus testing in Emergency Departments across Europe

Michael Rayment (United Kingdom)

Dorthe Raben (Denmark)

The rationale for BBV screening in Emergency Departments

10:45 - 10:55

	Michael Rayment (United Kingdom)	
	Understanding the numbers: BBV prevalence, data and monitoring	10:55 - 11:00
	Tamara Djuretic (United Kingdom)	
	Consent in Opt-Out BBV testing: legal, ethical, and practical considerations	11:00 - 11:05
	Jürgen K Rockstroh (Germany)	
	Operational integration and safe governance of ED BBV programs	11:05 - 11:10
	Emma Young (United Kingdom)	
	Panel / audience discussion on draft implementation guidance recommendations	11:10 - 11:25
	Tamara Djuretic (United Kingdom)	
	Jürgen K Rockstroh (Germany)	
	Emma Young (United Kingdom)	
	Summary and closing	11:25 - 11:30
	Michael Rayment (United Kingdom)	
<i>Special session</i>		
11:45 - 13:15		AMPHITHEATRE BORDEAUX
	SPS9 - EACS Standard of Care session	
	Milosz Parczewski (Poland)	
	Cristiana Oprea (Romania)	
	Setting the Scene - Using the Standards of Care to improve the Quality of Care and Outcomes	11:45 - 11:50
	Jürgen K Rockstroh (Germany)	
	ECDC/EACS Standards of HIV Care: Where are we at?	11:50 - 12:10
	Teymur Noori (Sweden)	
	Q&A	12:10 - 12:15
SPS9.1	PrEP Standards of Care: Results of the First European Clinical Audit	12:15 - 12:35
	Francesca Roper (Denmark)	
	Panel / audience Discussion on implementation of Standards of Care across Europe	12:35 - 13:00
	Sanjay Bhagani (United Kingdom)	
	Fiona Burns (United Kingdom)	
	Annette Haberl (Germany)	
	Milosz Parczewski (Poland)	
	Jürgen K Rockstroh (Germany)	
	Impact and future direction of Standards of Care	13:00 - 13:10
	Konstantinos Protopapas (Greece)	
	Summary and closing	13:10 - 13:15
	Cristiana Oprea (Romania)	
<i>Ceremony</i>		
13:15 - 13:45		AMPHITHEATRE BORDEAUX
	Closing remarks	
	Milosz Parczewski (Poland)	
	Karine Lacombe (France)	
	Jean-Michel Molina (France)	
	Bruno Spire (France)	
	Conference Closing Remarks	13:15 - 13:25
	Rapid Oral Abstract awards	13:25 - 13:30

Art Exhibition awards	13:30 - 13:35
Introduction to EACS 2027/21st European AIDS Conference	13:35 - 13:45